不稳定性心绞痛方证对应及证候动态变化研究
|
摘要
在中医学与现代医学的发展过程中,形成了辨证论治与辨病治疗的临床诊疗模式。病证结合已经成为目前中医研究的主要模式,方证对应是中医提高临床疗效的关键,将方剂与证候相结合进行研究,架起理法方药之间的桥梁,探求方剂与证候间的内在联系与规律,有利于提高辨证论治水平与临床疗效,因此病证结合方证对应是中西医结合研究的良好切入点。开展病证方结合方证对应研究,有助于丰富与完善中医理论体系与诊疗方法,对揭示经典方剂的作用机理及证候的本质都具有重要的意义。
冠心病是危害人类健康的一个主要疾病,已成为人群的主要死亡原因之一,因此冠心病的防治目前仍是医学研究的焦点之一。不稳定性心绞痛是冠心病的一个主要类型,属于现代医学急性冠脉综合症的范畴,其病情变化较快、凶险,需要及时诊治,现代医学已经形成了一套规范的诊疗标准。中医药在治疗冠心病方面具有一定的优势,在明确诊断疾病的基础上进行中医辨证治疗,能进一步提高疗效、提高生活质量、改善预后。本研究在病证结合的基础上,选择明确诊断的不稳定性心绞痛患者,采用经典名方血府逐瘀胶囊和生脉胶囊进行方证对应与不对应干预治疗,采集多时点的临床信息,从多方面阐释方证对应的作用机理,并探讨方证对应干预下的证候动态变化。
目的
探讨不稳定性心绞痛方证对应与不对应干预下的疗效及证候的动态变化,阐释方证对应的机理及证候的动态变化特征。
方法
入选88例经冠脉造影明确诊断的冠心病不稳定性心绞痛患者,血瘀证和气阴两虚证各44例,采用随机、双盲、双模拟的研究方法,分别用血府逐瘀胶囊和生脉胶囊进行方证对应与不对应干预治疗,收集治疗前、治疗后1周、2周、3周、4周的症状、中医证候、实验室指标及SAQ等相关信息。试验结束后：①进行两种干预方法的疗效比较,包括心绞痛疗效、心电图疗效、主要症状体征疗效、中医证候疗效、实验室指标疗效、生活质量疗效；②探讨不稳定性心绞痛在两种方法干预下证候的动态变化,应用生存分析和重复测量资料的方差分析方法,研究主要包括症状、证候要素频数、证候要素积分、证候要素组合及生物学标记物的动态变化特征。③探讨证候要素与生物学标记物之间的关系。
结果
1.疗效观察：试验过程中脱落6例,纳入统计分析的共有82例。①心绞痛疗效：血瘀证方证对应与不对应治疗有效率分别为80.95%、50.00%,方证对应优于不对应(P<0.05)；气阴两虚证方证对应与不对应治疗有效率分别为76.19%、55.00%,疗效无统计学意义(P>0.05)；总体方证对应与不对应治疗有效率分别为78.57%、52.50%,方证对应优于不对应(P<0.05)。②心电图疗效：方证对应与不对应治疗改善心电图总有效率为分别为73.81%、57.5%,比较无统计学意义(P>0.05)。③主要症状体征疗效：方证对应治疗在改善胸闷、心悸、倦怠乏力、气短、自汗优于不对应治疗(P<0.05),而在改善胸痛、畏寒肢冷、腰膝酸软、不寐等症状两种方法无差别(P>0.05)。④中医证候疗效：血瘀证方证对应与不对应治疗有效率分别为85.71%、50.00%,方证对应优于不对应(P<0.05)；气阴两虚证方证对应与不对应治疗有效率分别为80.95%、45.00%,方证对应优于不对应(P<0.05)；两证总体方证对应与不对应治疗有效率分别为83.33%47.50%,方证对应优于不对应(P<0.05)。⑤生物学标记物变化：hs-CRP、Hcy、MPO. MMP9、ET在血瘀证组方证对应治疗后下降(P＜0.05或P＜0.01),不对应治疗下降无统计学意义(P>0.05),对应治疗优于不对应(P<0.05)；在气阴两虚证组方证对应与不对应治疗后均有所下降(P<0.05或P<0.01),但两种方法差异无统计学意义(P＜0.05)；两个证型总体治疗后较治疗前均下降(P<0.05或P<0.01),且治疗后比较方证对应优于不对应(P<0.05)。PAF、PAG、BNP在血瘀证、气阴两虚证及总体治疗后均降低(P＜0.05或P<0.01),但治疗后各组间方证对应与不对应比较均无统计学意义(P＞0.05)。血脂四项：血瘀证、气阴两虚证及总体治疗后较治疗前比较,无论方证对应还是不对应差异均有统计学意义,TG、TC、LDL-C均下降(P<0.05), HDL-C均升高(P<0.05),但治疗后组间方证对应与不对应比较差异无统计学意义(P>0.05)。⑥SAQ疗效：各组治疗后AS、AF、TS、DP积分升高较治疗前比较差异具有统计学意义(P<0.05或P<0.01),两证总体方证对应与不对应治疗后比较亦有统计学意义(P<0.05)。各组PL积分治疗前后及治疗后组间比较差异均无统计学意义(P>0.05)。
2.证候动态变化：①症状变化：方证对应时,胸闷、心悸、自汗、气短症状消失的时间早于不对应治疗(P<0.05),而胸痛等其他症状消失时间无差别(P>0.05)；②证候要素频数变化：方证对应时,血瘀证、气虚证消失的时间要早于不对应治疗(P<0.05),而阴虚证的消失时间两种方法无统计学意义(P＞0.05)；③证候要素积分变化：方证对应时,血瘀证、气虚证、阴虚证积分下降要早于不对应治疗(P<0.05或P<0.01),血瘀证在治疗1周、气虚证、阴虚证在治疗2周后与治疗前比较即有统计学意义；不对应治疗时,血瘀证在治疗3周、气虚证、阴虚证在治疗4周后与治疗前比较才有统计学意义；④证候要素组合变化：方证对应时,在治疗过程中,2证组合逐渐增多,3证组合逐渐减少,而不对应治疗时2证组合逐渐减少,3证组合逐渐增多。⑤生物学标记物的变化：方证对应时,hs-CRP、Hcy、ET、MPO、MMP9在治疗1周后水平下降即有统计学意义(P<0.01),而方证不对应时MPO、MMP9治疗2周、hs-CRP、Hcy, ET治疗3周时水平下降才有统计学意义(P<0.01)。
3.证候要素与生物学标记物关系：血瘀证与PAF关系最为密切,提示血瘀可能与血小板活化有关；气虚证与BNP、PAG关系密切,提示气虚与心功能不全及血小板聚集有关；阴虚证与Hey、BNP、ET有一定关系,但三者的诊断贡献度均较小；气滞证与ET、MPO关系密切,提示气滞可能与内皮功能受损及炎症反应有关；痰浊证与TC、hs-CRP、TG关系最为密切,提示痰浊与血脂紊乱及炎症反应有关；热蕴证与hs-CRP、MMP9最为密切,提示热蕴可能与炎症反应有关；阳虚证与BNP密切相关,提示阳虚可能与心功能不全有关；寒凝证与BNP正相关,与Hey、MMP9负相关,提示寒凝可能与心功能不全有关,与炎症反应关系不大。
结论
1.不稳定性心绞痛在方证对应干预治疗时,心绞痛总疗效、症状如胸闷、心悸、气短、倦怠乏力、自汗疗效,中医证候疗效,部分生物学标记物如hs-CRP、Hey、MPO、MMP9、ET疗效,SAQ疗效,方证对应治疗均优于不对应治疗。
2.不稳定性心绞痛在方证对应干预时,胸闷、心悸、自汗、气短症状消失时间,血瘀证、气虚证两证候要素消失时间,血瘀证、气虚证、阴虚证积分下降时间,方证对应治疗要早于不对应治疗；在方证对应治疗时,证候要素组合朝着简单组合发展,在不对应治疗时朝着复杂组合发展；方证对应治疗时,部分生物学标记物下降时间要早于不对应。
3.证候要素与某些生物学标记物有一定的关系,可以为辨证提供参考依据。
During the development process of traditional chinese medicine (TCM) and modern medicine, clinical pattern of diagnosis and treatment about syndrome differentiation and treatment in TCM and treatment based on disease differentiation in modern medicine formed. Currently, the study on combination of disease and syndrome which lies in syndrome differentiation in TCM binding disease diagnosis in modern medicine has become the main pattern of syndrome. Combination of disease and syndrome with prescription corresponding to syndrome is the key of clinical effect. Combination of prescription and syndrome, putting up a bridge between principle-method-recipe-medicines,exploration of the internal relations of them, which can improve the level of clinical syndrome differentiation and treatment. Therefore, prescription corresponding to syndrome is the best starting point of integrative chinese and western medicine study. Carrying out the study of combination of disease and syndrome and prescription corresponding to syndrome contributes to enrich and perfect the theoretical system and treatment methods of TCM,which is of great significance for revealing the mechanism of the classic prescription and the essence of syndrome.
Coronary heart disease(CHD)is one of the main disease harmful to human health, which has become one of the leading causes of death, so prevention and treatment of CHD is still the focus of medical research. Unstable angina (UA), one of the major types of CHD, belongs to the scope of acute coronary syndrome(ACS).UA has characteristics of changing fast and danger, which should be diagnosed and treated timely. Modern medicine has become a series of standard for diagnosis and treatment, and TCM in treating CHD has its own advantages. With a clear diagnosis plus TCM treatment, it can further improve the efficacy, quality of life and improve prognosis. In this study, on the basis of combination of disease and syndrome, patients with UA who were diagnosed by coronary angiography(CAG) were selected to take part in this trial. Using the classic formula Xuefuzhuyu capsules and Shengmai capsules to interference UA with prescription corresponding to syndrome or non-corresponding, collecting clinical information multiple timepoint, to explain the mechanism of prescription corresponding to syndrome and to explore the dynamic change of syndrome under the guide of theory.
Purpose
To observe the effect and dynamic change of syndrome factors of UA intervened with prescription corresponding to syndrome or non-corresponding, and to explain the mechanism of prescription corresponding to syndrome and the dynamic change characteristics of syndrome.
Methods
88 cases with UA diagnosed by CAG were studied. including blood stasis group(44 cases), deficiency of both Qi and Yin group(44 cases). Using a randomized, double-blind, double dummy research methods, Xuefuzhuyu capsules and Shengmai capsules were administrated to intervene with patients. Clinical information were collected before and after treatment 1 week,2 weeks,3 weeks,4 weeks, including symptoms, signs, TCM syndrome and laboratory objective markers. After the test:①To compare the efficacy of two interventions, including angina pectoris, the main symptoms and signs, ECG effects, curative effect of TCM, laboratory markers of efficacy, quality of life effects;②To observe the dynamic change of syndrome of patients with UA in two interventional ways, using survival analysis and repeated measures analysis of variance methods, mainly including symptoms frequency, syndrome factor frequency, syndrome factor points, syndrome factors combination and biological markers③To explore the relationship between syndrome factors and biological markers.
Results
1. Comparison of therapeutic effects:During experimental period, six cases fell off, a total of 82 cases were involved into statistical analysis.①angina pectoris:the effective rate of prescription corresponding to syndrome and non-corresponding in blood stasis group was 80.95%,50.00%, respectively, the former was better than the latter(P＜0.05); the effective rate of prescription corresponding to syndrome and non-corresponding in deficiency of both Qi and Yin group was 76.19%,55.00%, respectively, there was no statistical significance (P>0.05); the total effective rate in prescription corresponding to syndrome and non-corresponding group was 78.57%,52.50%, respectively, the former is better than the latter (P＜0.05).②ECG effects:the effective rate of prescription corresponding to syndrome and non-corresponding in the whole group was 73.81%,57.5%, respectively, there was no statistical significance (P>0.05).③main symptoms and signs:the improvement of chest distress, palpitations, shortness of breath, malaise and fatigue, spontaneous perspiration in prescription corresponding to syndrome group was better than non-corresponding group (P＜0.05), but in improving the chest pain, aversion to cold, soreness of loins and knees, insomnia in the two group, there were no statistical significance(P>0.05).④TCM syndrome: the effective rate of prescription corresponding to syndrome and non-corresponding in blood stasis group was 85.71%,50.00%, respectively, while in deficiency of both Qi and Yin the rate was 80.95%,45.00%, respectively,the former is better than the latter (P＜0.05); the total effective rate in the whole group was 83.33%,47.50%, respectively, also, the former is better (P＜0.05).⑤biological markers:The level of hs-CRP, Hey, MPO, MMP9, ET in the blood stasis group treated with prescription corresponding to syndrome decreased after treatment (P<0.05 or P＜0.01), but they did not decrease in non-corresponding group (P>0.05),the former is better than the latter; while in deficiency of both Qi and Yin group all the five markers decreased despite of prescription corresponding to syndrome or not(P<0.05 or P<0.01)after treatment, but there were no ststistical significance between two kinds of methods; when comparison of all cases,these markers in those who were treated with prescription corresponding to syndrome decreased more than those treated with non-corresponding(P<0.05). The level of PAF, PAG, BNP after treatment in all groups were lower than that before treatment(P<0.05 or P＜0.01), but there were no statistical significance among the groups after treatment (P>0.05). Four Items of Blood-lipid Tests:there were statistical significance in lowering the level of TG, TC, LDL-C (P＜0.05), and increasing the level of HDL-C before and after treatment in each group (P<0.05), but there was no statistical significance between the two groups after treatment(P>0.05).⑥SAQ:before and after treatment in each group, AS, AF, TS, DP points decreased, there were statistical significance (P<0.05 or P<0.01), when added into all, points lowerd more in those who were treated with prescription corresponding to syndrome than those treated with non-corresponding (P＜0.05). PL points did not lower in each group before and after treatment (P>0.05).
2. Dynamic changes of syndrome:①symptoms:the disappearance time of chest distress, palpitations, spontaneous perspiration, shortness of breath symptoms in prescription corresponding to syndrome group was earlier than non-corresponding group(P<0.05), while there were no statistical significance about disappearance time of chest pain and other symptoms in non-corresponding group(P>0.05);②frequency of syndrome factors:when treated with prescription corresponding to syndrome, the onset time about blood stasis and Qi deficiency was earlier than non-corresponding (P＜0.05), while the onset time about Yin deficiency of two kinds of methods was not statistically significant(.P>0.05);③points of syndrome factors:when treated with prescription corresponding to syndrome, the onset time of syndrome points reduction about blood stasis, Qi deficiency, Yin deficiency was earlier than non-corresponding (P＜0.05 or P＜0.01), after treatment of 1 week in blood stasis and 2 weeks in Qi deficiency and Yin deficiency there were statistical significance, while it was as well after treatment of 3 weeks in blood stasis and 4 weeks in Qi deficiency and Yin deficiency when treated with non-corresponding,④combination of syndrome factors:when treated with prescription corresponding to syndrome, the combination of two syndromes gradually increased while the combination of three syndromes gradually decreased. when treated with non-corresponding, the change trend of combination of syndromes is contrary to that.⑤biological markers:when treated with prescription corresponding to syndrome, the level of hs-CRP, Hey, ET, MPO, MMP9 decreased after treatment of 1 week that is statistically significant (P<0.01), while treated with non-corresponding, the level of MPO, MMP9 fell after 2 weeks, and the level of hs-CRP, Hey, ET did after treatment for 3 weeks only, which showed statistical significance (P<0.01).
3. The relationship between syndrome factors and biological markers:Blood stasis syndrome and PAF was closely related which suggests the main pathology of blood stasis is platelet activation. Qi deficiency related BNP, PAG which suggests cardiac insufficiency and platelet aggregation. Yin deficiency was related to Hey, BNP and ET, but the degree of relation was minor and had little value for diagnosis. Qi stagnation was associated with ET, MPO which suggests inflammatory reaction and impaired endothelial function. Turbid phlegm well correlated TC, hs-CRP, TG. which implicate hyperlipemia and inflammatory reaction. Heat deposition was correlated with hs-CRP, MMP9 which hint inflammatory reaction. And also, Yang deficiency closely related to BNP which suggests cardiac insufficiency. Cold coagulation was associated with BNP, Hey, MMP9 which suggest cardiac insufficiency and inflammatory reaction.
Conclusion
1. Unstable angina treated with prescription corresponding to syndrome, the overall effect of angina, the effect of symptoms of chest distress, palpitations, shortness of breath, spontaneous perspiration, the effect of TCM syndrome, the effect of some biological marker such as hs-CRP, Hey, MPO,MMP9, ET, and SAQ efficacy were better than non-corresponding treatment.
2. Unstable angina treated with prescription corresponding to syndrome, the onset time of some symptoms such as chest distress, palpitations, spontaneous perspiration,shortness of breath, the disappearance time of syndrome factors such as blood stasis and Qi deficiency, the falling time of syndrome points of blood stasis,Qi deficiency and Yin deficiency were earlier than non-corresponding treatment. Combination of syndromes changed toward to simple trend when intervention with prescription corresponding to syndrome while varied toward to a complicated trend when intervention with non-corresponding. The onset time of some biological markers was earlier in prescription corresponding to syndrome treatment than non-corresponding treatment.
3. Syndrome factor has close relationship with some certain biological markers which can provide reference for the diagnosis.
冠心病是危害人类健康的一个主要疾病,已成为人群的主要死亡原因之一,因此冠心病的防治目前仍是医学研究的焦点之一。不稳定性心绞痛是冠心病的一个主要类型,属于现代医学急性冠脉综合症的范畴,其病情变化较快、凶险,需要及时诊治,现代医学已经形成了一套规范的诊疗标准。中医药在治疗冠心病方面具有一定的优势,在明确诊断疾病的基础上进行中医辨证治疗,能进一步提高疗效、提高生活质量、改善预后。本研究在病证结合的基础上,选择明确诊断的不稳定性心绞痛患者,采用经典名方血府逐瘀胶囊和生脉胶囊进行方证对应与不对应干预治疗,采集多时点的临床信息,从多方面阐释方证对应的作用机理,并探讨方证对应干预下的证候动态变化。
目的
探讨不稳定性心绞痛方证对应与不对应干预下的疗效及证候的动态变化,阐释方证对应的机理及证候的动态变化特征。
方法
入选88例经冠脉造影明确诊断的冠心病不稳定性心绞痛患者,血瘀证和气阴两虚证各44例,采用随机、双盲、双模拟的研究方法,分别用血府逐瘀胶囊和生脉胶囊进行方证对应与不对应干预治疗,收集治疗前、治疗后1周、2周、3周、4周的症状、中医证候、实验室指标及SAQ等相关信息。试验结束后：①进行两种干预方法的疗效比较,包括心绞痛疗效、心电图疗效、主要症状体征疗效、中医证候疗效、实验室指标疗效、生活质量疗效；②探讨不稳定性心绞痛在两种方法干预下证候的动态变化,应用生存分析和重复测量资料的方差分析方法,研究主要包括症状、证候要素频数、证候要素积分、证候要素组合及生物学标记物的动态变化特征。③探讨证候要素与生物学标记物之间的关系。
结果
1.疗效观察：试验过程中脱落6例,纳入统计分析的共有82例。①心绞痛疗效：血瘀证方证对应与不对应治疗有效率分别为80.95%、50.00%,方证对应优于不对应(P<0.05)；气阴两虚证方证对应与不对应治疗有效率分别为76.19%、55.00%,疗效无统计学意义(P>0.05)；总体方证对应与不对应治疗有效率分别为78.57%、52.50%,方证对应优于不对应(P<0.05)。②心电图疗效：方证对应与不对应治疗改善心电图总有效率为分别为73.81%、57.5%,比较无统计学意义(P>0.05)。③主要症状体征疗效：方证对应治疗在改善胸闷、心悸、倦怠乏力、气短、自汗优于不对应治疗(P<0.05),而在改善胸痛、畏寒肢冷、腰膝酸软、不寐等症状两种方法无差别(P>0.05)。④中医证候疗效：血瘀证方证对应与不对应治疗有效率分别为85.71%、50.00%,方证对应优于不对应(P<0.05)；气阴两虚证方证对应与不对应治疗有效率分别为80.95%、45.00%,方证对应优于不对应(P<0.05)；两证总体方证对应与不对应治疗有效率分别为83.33%47.50%,方证对应优于不对应(P<0.05)。⑤生物学标记物变化：hs-CRP、Hcy、MPO. MMP9、ET在血瘀证组方证对应治疗后下降(P＜0.05或P＜0.01),不对应治疗下降无统计学意义(P>0.05),对应治疗优于不对应(P<0.05)；在气阴两虚证组方证对应与不对应治疗后均有所下降(P<0.05或P<0.01),但两种方法差异无统计学意义(P＜0.05)；两个证型总体治疗后较治疗前均下降(P<0.05或P<0.01),且治疗后比较方证对应优于不对应(P<0.05)。PAF、PAG、BNP在血瘀证、气阴两虚证及总体治疗后均降低(P＜0.05或P<0.01),但治疗后各组间方证对应与不对应比较均无统计学意义(P＞0.05)。血脂四项：血瘀证、气阴两虚证及总体治疗后较治疗前比较,无论方证对应还是不对应差异均有统计学意义,TG、TC、LDL-C均下降(P<0.05), HDL-C均升高(P<0.05),但治疗后组间方证对应与不对应比较差异无统计学意义(P>0.05)。⑥SAQ疗效：各组治疗后AS、AF、TS、DP积分升高较治疗前比较差异具有统计学意义(P<0.05或P<0.01),两证总体方证对应与不对应治疗后比较亦有统计学意义(P<0.05)。各组PL积分治疗前后及治疗后组间比较差异均无统计学意义(P>0.05)。
2.证候动态变化：①症状变化：方证对应时,胸闷、心悸、自汗、气短症状消失的时间早于不对应治疗(P<0.05),而胸痛等其他症状消失时间无差别(P>0.05)；②证候要素频数变化：方证对应时,血瘀证、气虚证消失的时间要早于不对应治疗(P<0.05),而阴虚证的消失时间两种方法无统计学意义(P＞0.05)；③证候要素积分变化：方证对应时,血瘀证、气虚证、阴虚证积分下降要早于不对应治疗(P<0.05或P<0.01),血瘀证在治疗1周、气虚证、阴虚证在治疗2周后与治疗前比较即有统计学意义；不对应治疗时,血瘀证在治疗3周、气虚证、阴虚证在治疗4周后与治疗前比较才有统计学意义；④证候要素组合变化：方证对应时,在治疗过程中,2证组合逐渐增多,3证组合逐渐减少,而不对应治疗时2证组合逐渐减少,3证组合逐渐增多。⑤生物学标记物的变化：方证对应时,hs-CRP、Hcy、ET、MPO、MMP9在治疗1周后水平下降即有统计学意义(P<0.01),而方证不对应时MPO、MMP9治疗2周、hs-CRP、Hcy, ET治疗3周时水平下降才有统计学意义(P<0.01)。
3.证候要素与生物学标记物关系：血瘀证与PAF关系最为密切,提示血瘀可能与血小板活化有关；气虚证与BNP、PAG关系密切,提示气虚与心功能不全及血小板聚集有关；阴虚证与Hey、BNP、ET有一定关系,但三者的诊断贡献度均较小；气滞证与ET、MPO关系密切,提示气滞可能与内皮功能受损及炎症反应有关；痰浊证与TC、hs-CRP、TG关系最为密切,提示痰浊与血脂紊乱及炎症反应有关；热蕴证与hs-CRP、MMP9最为密切,提示热蕴可能与炎症反应有关；阳虚证与BNP密切相关,提示阳虚可能与心功能不全有关；寒凝证与BNP正相关,与Hey、MMP9负相关,提示寒凝可能与心功能不全有关,与炎症反应关系不大。
结论
1.不稳定性心绞痛在方证对应干预治疗时,心绞痛总疗效、症状如胸闷、心悸、气短、倦怠乏力、自汗疗效,中医证候疗效,部分生物学标记物如hs-CRP、Hey、MPO、MMP9、ET疗效,SAQ疗效,方证对应治疗均优于不对应治疗。
2.不稳定性心绞痛在方证对应干预时,胸闷、心悸、自汗、气短症状消失时间,血瘀证、气虚证两证候要素消失时间,血瘀证、气虚证、阴虚证积分下降时间,方证对应治疗要早于不对应治疗；在方证对应治疗时,证候要素组合朝着简单组合发展,在不对应治疗时朝着复杂组合发展；方证对应治疗时,部分生物学标记物下降时间要早于不对应。
3.证候要素与某些生物学标记物有一定的关系,可以为辨证提供参考依据。
During the development process of traditional chinese medicine (TCM) and modern medicine, clinical pattern of diagnosis and treatment about syndrome differentiation and treatment in TCM and treatment based on disease differentiation in modern medicine formed. Currently, the study on combination of disease and syndrome which lies in syndrome differentiation in TCM binding disease diagnosis in modern medicine has become the main pattern of syndrome. Combination of disease and syndrome with prescription corresponding to syndrome is the key of clinical effect. Combination of prescription and syndrome, putting up a bridge between principle-method-recipe-medicines,exploration of the internal relations of them, which can improve the level of clinical syndrome differentiation and treatment. Therefore, prescription corresponding to syndrome is the best starting point of integrative chinese and western medicine study. Carrying out the study of combination of disease and syndrome and prescription corresponding to syndrome contributes to enrich and perfect the theoretical system and treatment methods of TCM,which is of great significance for revealing the mechanism of the classic prescription and the essence of syndrome.
Coronary heart disease(CHD)is one of the main disease harmful to human health, which has become one of the leading causes of death, so prevention and treatment of CHD is still the focus of medical research. Unstable angina (UA), one of the major types of CHD, belongs to the scope of acute coronary syndrome(ACS).UA has characteristics of changing fast and danger, which should be diagnosed and treated timely. Modern medicine has become a series of standard for diagnosis and treatment, and TCM in treating CHD has its own advantages. With a clear diagnosis plus TCM treatment, it can further improve the efficacy, quality of life and improve prognosis. In this study, on the basis of combination of disease and syndrome, patients with UA who were diagnosed by coronary angiography(CAG) were selected to take part in this trial. Using the classic formula Xuefuzhuyu capsules and Shengmai capsules to interference UA with prescription corresponding to syndrome or non-corresponding, collecting clinical information multiple timepoint, to explain the mechanism of prescription corresponding to syndrome and to explore the dynamic change of syndrome under the guide of theory.
Purpose
To observe the effect and dynamic change of syndrome factors of UA intervened with prescription corresponding to syndrome or non-corresponding, and to explain the mechanism of prescription corresponding to syndrome and the dynamic change characteristics of syndrome.
Methods
88 cases with UA diagnosed by CAG were studied. including blood stasis group(44 cases), deficiency of both Qi and Yin group(44 cases). Using a randomized, double-blind, double dummy research methods, Xuefuzhuyu capsules and Shengmai capsules were administrated to intervene with patients. Clinical information were collected before and after treatment 1 week,2 weeks,3 weeks,4 weeks, including symptoms, signs, TCM syndrome and laboratory objective markers. After the test:①To compare the efficacy of two interventions, including angina pectoris, the main symptoms and signs, ECG effects, curative effect of TCM, laboratory markers of efficacy, quality of life effects;②To observe the dynamic change of syndrome of patients with UA in two interventional ways, using survival analysis and repeated measures analysis of variance methods, mainly including symptoms frequency, syndrome factor frequency, syndrome factor points, syndrome factors combination and biological markers③To explore the relationship between syndrome factors and biological markers.
Results
1. Comparison of therapeutic effects:During experimental period, six cases fell off, a total of 82 cases were involved into statistical analysis.①angina pectoris:the effective rate of prescription corresponding to syndrome and non-corresponding in blood stasis group was 80.95%,50.00%, respectively, the former was better than the latter(P＜0.05); the effective rate of prescription corresponding to syndrome and non-corresponding in deficiency of both Qi and Yin group was 76.19%,55.00%, respectively, there was no statistical significance (P>0.05); the total effective rate in prescription corresponding to syndrome and non-corresponding group was 78.57%,52.50%, respectively, the former is better than the latter (P＜0.05).②ECG effects:the effective rate of prescription corresponding to syndrome and non-corresponding in the whole group was 73.81%,57.5%, respectively, there was no statistical significance (P>0.05).③main symptoms and signs:the improvement of chest distress, palpitations, shortness of breath, malaise and fatigue, spontaneous perspiration in prescription corresponding to syndrome group was better than non-corresponding group (P＜0.05), but in improving the chest pain, aversion to cold, soreness of loins and knees, insomnia in the two group, there were no statistical significance(P>0.05).④TCM syndrome: the effective rate of prescription corresponding to syndrome and non-corresponding in blood stasis group was 85.71%,50.00%, respectively, while in deficiency of both Qi and Yin the rate was 80.95%,45.00%, respectively,the former is better than the latter (P＜0.05); the total effective rate in the whole group was 83.33%,47.50%, respectively, also, the former is better (P＜0.05).⑤biological markers:The level of hs-CRP, Hey, MPO, MMP9, ET in the blood stasis group treated with prescription corresponding to syndrome decreased after treatment (P<0.05 or P＜0.01), but they did not decrease in non-corresponding group (P>0.05),the former is better than the latter; while in deficiency of both Qi and Yin group all the five markers decreased despite of prescription corresponding to syndrome or not(P<0.05 or P<0.01)after treatment, but there were no ststistical significance between two kinds of methods; when comparison of all cases,these markers in those who were treated with prescription corresponding to syndrome decreased more than those treated with non-corresponding(P<0.05). The level of PAF, PAG, BNP after treatment in all groups were lower than that before treatment(P<0.05 or P＜0.01), but there were no statistical significance among the groups after treatment (P>0.05). Four Items of Blood-lipid Tests:there were statistical significance in lowering the level of TG, TC, LDL-C (P＜0.05), and increasing the level of HDL-C before and after treatment in each group (P<0.05), but there was no statistical significance between the two groups after treatment(P>0.05).⑥SAQ:before and after treatment in each group, AS, AF, TS, DP points decreased, there were statistical significance (P<0.05 or P<0.01), when added into all, points lowerd more in those who were treated with prescription corresponding to syndrome than those treated with non-corresponding (P＜0.05). PL points did not lower in each group before and after treatment (P>0.05).
2. Dynamic changes of syndrome:①symptoms:the disappearance time of chest distress, palpitations, spontaneous perspiration, shortness of breath symptoms in prescription corresponding to syndrome group was earlier than non-corresponding group(P<0.05), while there were no statistical significance about disappearance time of chest pain and other symptoms in non-corresponding group(P>0.05);②frequency of syndrome factors:when treated with prescription corresponding to syndrome, the onset time about blood stasis and Qi deficiency was earlier than non-corresponding (P＜0.05), while the onset time about Yin deficiency of two kinds of methods was not statistically significant(.P>0.05);③points of syndrome factors:when treated with prescription corresponding to syndrome, the onset time of syndrome points reduction about blood stasis, Qi deficiency, Yin deficiency was earlier than non-corresponding (P＜0.05 or P＜0.01), after treatment of 1 week in blood stasis and 2 weeks in Qi deficiency and Yin deficiency there were statistical significance, while it was as well after treatment of 3 weeks in blood stasis and 4 weeks in Qi deficiency and Yin deficiency when treated with non-corresponding,④combination of syndrome factors:when treated with prescription corresponding to syndrome, the combination of two syndromes gradually increased while the combination of three syndromes gradually decreased. when treated with non-corresponding, the change trend of combination of syndromes is contrary to that.⑤biological markers:when treated with prescription corresponding to syndrome, the level of hs-CRP, Hey, ET, MPO, MMP9 decreased after treatment of 1 week that is statistically significant (P<0.01), while treated with non-corresponding, the level of MPO, MMP9 fell after 2 weeks, and the level of hs-CRP, Hey, ET did after treatment for 3 weeks only, which showed statistical significance (P<0.01).
3. The relationship between syndrome factors and biological markers:Blood stasis syndrome and PAF was closely related which suggests the main pathology of blood stasis is platelet activation. Qi deficiency related BNP, PAG which suggests cardiac insufficiency and platelet aggregation. Yin deficiency was related to Hey, BNP and ET, but the degree of relation was minor and had little value for diagnosis. Qi stagnation was associated with ET, MPO which suggests inflammatory reaction and impaired endothelial function. Turbid phlegm well correlated TC, hs-CRP, TG. which implicate hyperlipemia and inflammatory reaction. Heat deposition was correlated with hs-CRP, MMP9 which hint inflammatory reaction. And also, Yang deficiency closely related to BNP which suggests cardiac insufficiency. Cold coagulation was associated with BNP, Hey, MMP9 which suggest cardiac insufficiency and inflammatory reaction.
Conclusion
1. Unstable angina treated with prescription corresponding to syndrome, the overall effect of angina, the effect of symptoms of chest distress, palpitations, shortness of breath, spontaneous perspiration, the effect of TCM syndrome, the effect of some biological marker such as hs-CRP, Hey, MPO,MMP9, ET, and SAQ efficacy were better than non-corresponding treatment.
2. Unstable angina treated with prescription corresponding to syndrome, the onset time of some symptoms such as chest distress, palpitations, spontaneous perspiration,shortness of breath, the disappearance time of syndrome factors such as blood stasis and Qi deficiency, the falling time of syndrome points of blood stasis,Qi deficiency and Yin deficiency were earlier than non-corresponding treatment. Combination of syndromes changed toward to simple trend when intervention with prescription corresponding to syndrome while varied toward to a complicated trend when intervention with non-corresponding. The onset time of some biological markers was earlier in prescription corresponding to syndrome treatment than non-corresponding treatment.
3. Syndrome factor has close relationship with some certain biological markers which can provide reference for the diagnosis.
引文
1.童舜华,童瑶,段逸山.《黄帝内经》病证结合论治思想的萌芽[J].辽宁中医学院学报,2003,5(1)：14.
2.耿晓娟,张军平.试论病证结合、方证对应与辨证论治[J].中医杂志,2008,49(9)：775-777.
3.姚魁武,王阶,朱翠玲,等.不同疾病血瘀证量化诊断的比较研究[J].辽宁中医杂志,2006,33(11)：1381-1382.
4.邢雁伟,王阶,姚魁武,等.对1022例血瘀证患者基于对应相关方法的客观量化研究[J].北京中医大学学报,2007,30(8)：556-559.
5.衷敬柏,王阶,赵宜军,等.病证结合与方证相应研究[J].辽宁中医杂志,2006,33(2)：137-139.
6.杜武勋.关于中西医结合证病结合的疾病诊断思维模式探讨[J].天津中医学院学报,2002,21(2)：12-13.
7.李敬林,王太一,王禄增,等.2型糖尿病证病结合动物模型的研究[J].中国比较医学杂志,2007,17(8)：473-475.
8.孙广仁,王洪武,高博,等.COPD寒饮蕴肺证大鼠病证结合模型的建立[J].山东中医药大学学报,2007,31(3)：242-244.
9.刘丽梅,陈琳,王瑞海,等.病证结合方证相应基础研究的现状[J].中国中医基础医学杂志,2009,15(5)：334-336.
10.谢元华,张京春,陈可冀.病证方药相应及其意义[J].中西医结合心脑血管病杂志,2008,6(1)：1-2.
11.陈可冀,宋军.病证结合的临床研究是中西医结合研究的重要模式[J].继续医学教育,2007,21(19)：12-15.
12.朱邦贤.“方证相对”是中医辨证论治法则乏魂[J].上海中医药杂志,2006,40(8)：52-54.
13.李瑞,尹英杰,林殷,鲁兆麟.中医方证客观化研究初探[J].北京中医药大学学报,2002,25(3)：6-11.
14.金海浩.中医学的方证相应论[J].黑龙江中医药,2005,1：44-46.
15.谢鸣.“方证相关”逻辑命题及其意义[J].北京中医药大学学报,2003,3(26)：11-12.
16.沈自尹.有关证与神经内分泌免疫网络的研究[J].中医药学刊,2003,21(1)：10-14.
17.王学良,李赛美.方证规范化研究的意义及方法探讨[J].广州中医药大学学报,2009,26(1)：83-85.
18.王玉川.关于“有是证、用是方”的反思[J].北京中医药大学学报,1998,21(6)：2-4.
19.贾春华,王永炎,黄启福,等.以方测证法不可行论[J].辽宁中医杂志,2006,33(12)：1549-1550.
20.陈云慧,王燕,张昱,等.基于贝叶斯方法的方证相应研究[J].辽宁中医杂志,2008,35(3)：360-362.
21.吴昊,李书琴,董记华.基于粗糙集理论的中医方证相关性分析模型的研究[J].现代电子技术,2007(24)：75-78.
22.叶任高,陆再英.内科学.第6版.北京：人民卫生出版社,2004.
23.邵念方,骆丰,许荣廷.冠心病中西医综合治疗.北京：人民卫生出版社,2004.
24.Rosenson RS, Tangney CC. Antiatherothromboic properties of stains. ImPlication for cardiovascular event reduction[J]. JAMA,1998,279:1643-1650.
25.NaghaviM, Libbyp, Falk E, et al.From vulnerable plaque to vulnerable patient.A call for new definition and risk assessment strategies [J]. Part1.Circulation,2003,108:1664-1672.
26.张长群.不稳定型心绞痛的诊断和治疗[J].现代医药卫生,2005,21(15)：1986-1987.
1.郭蕾,王永炎,张志斌.证候概念的诠释[J].北京中医药大学学报,2003,22(2)：5.
2.王永炎.完善中医辨证方法体系的建议[J].中医杂志,2004,45(10)：729.
3.黄东平.中医古籍对心力衰竭的论述探要[J].中医药学刊,2003,21(4)：592-593.
4.杨培君,杨磊.充血性心力衰竭的中医证治概要[J].陕西中医学院学报,2002,25(1)：2-5.
5.黄东平,罗懿明,黄衍寿,等.充血性心力衰竭中医证型及其演变规律的临床观察[J].中西医结合心脑血管病杂志,2003,1(12)：685-686.
6.于涛,曹洪欣.胸痹(冠心病)病机演变探微[J].中医药信息,2004,21(4)：1-2.
7.韩丽萍,刘实.骨质疏松症中医证候的演变规律[J].中华中医药学刊,2008,26(12)：2601-2602.
8.吕维柏.艾滋病中西医防治学[M].北京：人民卫生出版社,1994：144.
9.杨凤珍.HIV/AIDS中医分期辨证治疗[J].中国医学报,2004,19(4)：240-242.
10.陈江.溃疡性结肠炎中医病机演变及证治探讨[J].新中医,2005,37(4)：11-12.
11.周俊元.常见急腹症的演变规律及辨证施治研究[J].中医杂志,1986,1：59-62.
12.窦志芳,郭蕾,张俊龙,等.中风病证候动态时空特征研究的思考[J].中西医结合,脑血管病杂志,2006,4(2)：139-140.
13.岑玉文.HIV/AIDS中医证型、证型演变及其与T淋巴细胞活化关系的研究观察：[博士学位论文].广州：广州中医药大学,2008.
14.刘渊,安莉萍.骨关节病中医证型分布及演变规律的研究[J].现代中西医结合杂志,2008,17(13)：1950-1951.
15.聂峰.慢性肾衰竭辨证规范化及中医证候规律的研究：[硕士学位论文].广州：第一军医大学,2005.
16.刘恩顺,孙增涛,封继宏,等.天津市支气管哮喘证候分布及演变规律的临床流行病学调查[J].辽宁中医药大学学报,2008,10(9)：126-127.
17.陈霞.肠易激综合征的证候演变规律研究：[硕士学位论文].成都：成都中医药大学,2003.
18.刘绍能,陶夏平,王融冰,等.慢性乙型肝炎中医证候演变规律研究[J].中国中医药科技,2008,15(3)：161-163.
19.唐智敏,辛伟,瞿晓东,等.肝硬化肝功储备力与中医证型演变的关系[J].中西医结 合肝病杂志,1993,3(4)：5-7.
20.张广中,王萍,王莒生,等.2651例寻常型银屑病中医证候分布和演变规律研究[J].中医杂志,2008,49(10)：894-895.
21.张磊,张光华,刘文涛,等.胃院痛证候的演变规律[J].成都中医药大学学报,1995,18(4)：19-22.
22.任宏义,和贵童,张玉枝.脾虚证证型演变规律的探讨-508例慢性萎缩性胃炎的临床病理分析[J].山东中医学院学报,1992,16(4)：43-36.
23.张明雪,曹洪欣,常艳鹏.冠心病(稳定性心绞痛)证候演变规律研究[J].中华中医药杂志,2010,25(1)：24-27.
24.薛增明,李长生,宁美芳,等.42例冠心病患者冠状动脉支架植入术前后中医证型的演变[J].山东中医杂志,2005,24(12)：719-720.
25.高婷.90例慢性肾衰竭并肾性骨病的证候演变规律初探：[硕士学位论文].湖北：湖北中医学院,2006.
26.孙舒敏.中晚期原发性非小细胞肺癌化疗前后中医证候演变规律探讨：[硕士学位论文].北京：北京中医药大学,2008.
27.黄建龙,李云辉,林中平,等.120例重型颅脑损伤急性期中医证型及演变规律临床研究[J].中医研究,2005,18(9)：19-22.
28.曾普华, 刘伟胜, 潘敏求,等.原发性肝癌围血管介入期中医证候演变规律初探[J].湖南中医药大学学报,2008,28(3)：54-56.
29.袁芳.鼻咽癌放疗前、中、后的证型分布及其演变规律的研究：[硕士学位论文].广州：广州中医药大学,2007.
30.范洪,侯英荣,郑晓丽,等.163例细菌感染性呼吸系统疾病的中医证型演变规律研究[J].中医研究,2006,19(2)：24-26.
31.范洪,侯英荣,兰洪英.呼吸系统真菌感染中医证型演变规律的研究[J].世界中西医结合杂志,2008,3(1)：39-40.
32.王雪峰,董丹,虞坚尔,等.小儿肺炎中医证候演变规律研究[J].中医杂志,2005,46(5)：374-376.
33.王雪峰,董丹,虞坚尔,等.儿童肺炎常见病原学分析及中医证候演变规律的多中心随机双盲安慰剂对照试验研究[J].中国循证儿科杂志,2006,1(3)：170-176.
34.吕玉霞,杜艳玲,董彩风,等.小儿肺炎中医证候分布特点及证型演变特点的临床研究[J].中医儿科杂志,2008,4(3)：13-17.
35.谢颖桢,邹忆怀,马洪明,等.中风病急性期中经络和中脏腑证候要素的动态比较[J].中国中医基础医学杂志,2006,12(10)：746-748.
36.马斌,高颖.中风病发病第7天证候要素的初步分析[J].中国中医基础医学杂志,2006,12(07)：494-496.
37.刘强,高颖.中风病不同阶段四诊信息的指标聚类分析[J].中华中医药杂志,2007,22(3)：162-164.
38.马斌,高颖.中风病发病第7天和第14天证候要素演变规律初步研究[J].辽宁中医杂志,2006,33(12)：1561-1563.
39.马斌,高颖.中风病恢复期证候要素的研究[J].江苏中医药,2007,39(01)：27-29.
40.薛晓琳.慢性疲劳综合征的症证特征、演变及预后转归规律的初步研究：[硕士学位论文].北京：北京中医药大学,2003.
41.高坤,孙伟,周栋,等.慢性肾脏病中医证型分布及演变规律研究[J].江苏中医药,2008,40(6)：33-35.
42.李同侠.慢性肾衰肾性骨病中医证候分布特征及演变的研究：[硕士学位论文].北京：中国中医科学院,2006.
1.1980年全国冠心病辨证论治研究座谈会.冠心病中医辨证试行标准[J].中医杂志,1980,21(8)：46.
2.陈贵延,薛赛琴,最新国内外疾病诊疗标准[M].第1版.北京：学苑出版社1992：209-212,678-686.
3.中西医结合学会心血管专业委员会.冠心病中医辨证标准[J].中西医结合杂志,1991,11(5)：257.
4.中华人民共和国卫生部.中药新药临床研究指导原则：第1辑[S].1993：41.
5.国家中医药管理局·中医病证诊断疗效标准[S].南京：南京大学出版社,1994：18-19.
6.郑筱萸.中药新药临床研究指导原则(试行)[M].北京：中国医药科技出版社,2002：68-73.
7.王永炎主编.中医内科学[M].上海：上海科学技术出版社,1997.
8.谭日强.冠心病的辨证分型论治[J].湖南中医学院学报,1986,1：17-19.
9.陶克文.胸痹心痛证治体会[J].实用中医药杂志,1994,(3)：3.
10.沈绍功.诊治冠心病的新思路[J].中国中医急症,1999,8(2)：51.
11周文泉.冠心病心绞痛辨证论治研究进展[J].新中医,1980,12(5)：43.
12.王鹏.冠心病心绞痛辨证论治研究的现状及分析[J].中国中医药信息杂志,1997,4(5)：23-24.
13.宋秀明.王左治疗冠心病的经脸.湖北中医杂志,1999,21(5)：197.
14.李幼勋,王德华.胸痹的病因病机及其证治述略[J].实用中医内科杂志,2002,16(4)：184-1857.
15.王文革,姚红芳.冠心病心绞痛的中医辨证分析[J].中西医结合心脑血管病杂志,2004,2(12)：730.
16.胡东斐.胸痹证治文献研究[J].山东中医药大学学报,2005,29(1)：37-40.
17.郭志华.冠心病心绞痛2432例中医辨证分型综合统计分析[J].湖南中医杂志,1998,14(2)：7-8.
18.旷惠桃,潘远根.冠心病心绞痛临床证型分类探讨[J].中医杂志,1997,38(12)：742.
19.衷敬柏,董绍英,王阶,等.2689例冠心病心绞痛证候要素的文献统计分析[J].中国中医药信息杂志,2006,13(5)：100-101.
20.张琳,于鑫婷,徐浩.冠心病中医证候特点的分析与思考[J].中西医结合心脑血管病杂志,2009,7(5)：578-580.
21.张秋雁,邓冰湘.冠心病心绞痛临床中医证型分布的回顾性分析[J].中医研究,2005,18(11)：23-24.
22.李军,王阶.冠心病心绞痛证候要素与应证组合的5099例文献病例分析[J].中国中医基础医学杂志,2007,13(12)：926-927.
23.晏峻峰,朱文锋.粗糙集理论在中医证素辨证研究中的应用[J].中国中医基础医学杂志,2006,12(2)：90-93.
24.马静娴.冠心病心绞痛辨证施治疗效观察[J].黑龙江中医药,1991,(2)：13.
25.王永霞,胡宇才,朱明军,等.冠心病心绞痛中医证候分布相关性研究[J].世界中西医结合杂志,2008,39(12)：714-716.
26.刘德桓,许真真,郭伟聪.冠心病心绞痛395例中医证型特点探讨[J].中医杂志,1995,36(10)：617-618.
27.郝惠莉,王明亮.辨证分型治疗冠心病心绞痛172例[J].浙江中医杂志,1996,31(1)：13.
28.黄腾蛟,嵇美霞,史大卓.111例冠心病中医辨证分型研究[J].现代中西医结合杂志,2004,13(2)：172.
29.吴辉,于扬文,吴伟,等.116例冠心病患者中医证候及病因分析[J].江苏中医药,2004,25(10)：30-31.
30.何庆勇,王阶,姚魁武,等.1069例冠心病脏腑虚证的多中心前瞻性研究[J].中华中医药杂志,2009,24(1)：31-33.
31.韦湘林.135例冠心病的中医证型及舌脉象分析[J].新中医,1996,1：8-10.
32.姚笛,王忆勤,李福凤,等.187例冠心病病例临床证型观察[J].辽宁中医杂志,2009,36(6)：930-933.
33.李晋宏.213例冠心病中医辨证分型研究[J].陕西中医,2006,27(2)：149-150.
34.王阶,李军,姚魁武,等.冠心病心绞痛证候要素与应证组合研究[J].中医杂志,2007,48(10)：920-922.
35.董国菊,刘剑刚,王承龙,等.300例冠心病患者中医证型分布特点分析[J].环球中医药,2009,2(2)：96-98.
36.吴焕林,阮新民,杨小波,等.319例冠心病患者证候分布规律分析[J].中国中西医结合杂志,2007,27(6)：498-500.
37.石刚,刘婷,程丑夫.冠心病常见证候临床流行病学调查[J].中华中医药学刊,2007,25(8)：1675-1676.
38.吴肠,王轩,崔杰,等.348例冠心病患者中医证候特点因子分析[J].中华中医药学刊,2009,27(2)：392-394.
39.刘永家.382例冠心病中医证型分布与病因关系[J].辽宁中医学院学报,2000,2(4)：245.
40.贾振华,王永军,吴以岭,等.基于熵的复杂系统分划方法与冠心病心绞痛证候要素提取及其分布规律[J].第二军医大学学报,2007,28(7)：775-777.
41.邢雁伟,王阶,衷敬柏,等.采用聚类分析和对应相关方法研究1069例冠心病心绞痛证候应证组合规律[J].中华中医药杂志,2007,22(11)：747-750.
42.周中山.冠心病心绞痛中医证型与血液流变学的相关性研究[J].湖南中医药导报,2001,7(7)：360-361.
43.陈炳旺,蔺德明.冠心病中医实证血液流变学变化的临床研究[J].福建中医学院学报,2000,10(1)：1-3.
44.吕芳芳,黄文.冠心病心绞痛不同证型与血液流变关系的探讨[J].北京中医,2004,23(6)：327-328.
45.丘瑞香,罗致强,朱雅宣,等.冠心病血瘀证血液理化特性与中医证型相关性研究.中医杂志,2002,43(5)：378-379.
46.王桂玲,王磊,王忠爱,等.冠心病的中医辨证分型与血液流变学指标的关系[J].实用心电学杂志,2007,16(2)：124-125.
47.刘辛光.冠心病辨证分型与血液动力学流变学变化关系探析[J].辽宁中医杂志,2005, 32(10)：991.
48.陈宝珍,胡志希,袁肇凯,等.53例早发冠心病心血瘀阻证甲襞微循环的检测分析[J].中西医结合心脑血管病杂志,2007,5(9)：803-804.
49.郭平清,林求诚,郭银庚,等.冠心病肾阳虚证血脂特点.浙江中西医结合杂志,2003,13(4)：208-2-10.
50.谢海波,陈新宇,石刚,等.冠心病心绞痛中医证型与C反应蛋白血脂的相关性研究[J].湖南中医学院学报,2005,25(4)：32-34.
51.其其格,王伟,毕力夫,等.冠心病血瘀证与血脂血尿酸关系的探讨[J].辽宁中医杂志,2008,35(12)：1826-1827.
52.邓奕辉,李定祥,杨军辉.冠心病心绞痛血瘀证四亚型与血脂的相关性研究[J].湖南中医杂志,2008,24(1)：59；100.
53.袁肇凯,田松,黄献平,等.冠心病痰瘀证候血脂指标的Meta分析[J].云南中医学院学报,2008,31(5)：1-3.
54.冉旭,林凯旋,安辉,等.冠心病的中医辨证分型与同型半胱氨酸的相关性研究[J].中西医结合心脑血管病杂志,2007,5(8)：750-751.
55.林凯旋,安辉,缪灿铭,等.冠心病血瘀证与同型半胱氨酸的相关性研究[J].中医研究,2007,20(2)：32-33.
56.严卉,胡晓晟,陈君柱,等.血浆同型半胱氨酸和冠状动脉粥样硬化严重程度与中医证型的关系[J].中国中西医结合杂志,2002,22(11)：813-816.
57.卢玉俊,石磊.冠心病中医证型与血浆同型半胱氨酸水平相关性的研究[J].浙江中医药大学学报,2009,33(1)：103-104.
58.方显明,唐耀平,郑德俊.冠心病血浆同型半胧氨酸与中医证型的相关性[J].中医杂志2005,46(10)：775-776.
59.孔丽君.冠心病患者血浆同型半胱氨酸水平与辨证分型相关性研究[J].实用中西医结合临床,2004,4(1)：7-8.
60.李超,安冬青,王娟,等.冠心病秽浊痰阻证与血浆同型半胱氨酸的相关性研究[J].中西医结合心脑血管病杂志,2008,6(4)：384-385.
61.商秀洋,石洁.冠心病中医辨证与血清高敏C反应蛋白的关系研究[J].现代中西医结合杂志,2008,17(6)：818-819.
62.王强,黄绍湘,刘钧超,等.冠心病血瘀证与超敏c-反应蛋白关系的临床探讨[J].广西中医药,2005,28(3)：7-8.
63.林超,郭进建,林青,等.高敏c反应蛋白与不稳定型心绞痛中医证型相关性研究[J].中国中医急症,2007,16(10)：1221-1223.
64.石刚,刘婷.冠心病及其常见中医证型与超敏c反应蛋白的关系探讨[J].中医药临床杂志,2007,19(1)：29-30.
65.杨徐杭,汶医宁,魏敏慧,等.冠心病中医辨证与血清c反应蛋白的相关性研究[J].中医药学刊,2004,22(9)：1649-1650..
66.杨徐杭,汶医宁,王军威,等.冠心病中医辨证与血清IL-18、 sCD40L的关系[J].江苏中医药,2009,41(3)：41-42.
67.刘艳,叶武,王坤根,等.冠心病痰瘀辨证与相关炎症标志物关系初探[J].中华中医药杂志,2008,23(12)：1121-1124.
68.毛以林,李旭,彭素娟,等.冠心病血瘀证与高敏C-反应蛋白相关性研究[J].中国中医药信息杂志,2007,14(8)：26-27.
69.易自刚,王强,张双旗.急性冠脉综合征中医证型与IL-18. Hs-CRP的相关性研究[J].江苏中医药,2007,39(12)：22-23.
70.郑峰,曲丹,徐浩,等.冠心病稳定期患者中医辨证与超敏C反应蛋白相关性研究[J].中国中西医结合杂志,2009,29(6)485-487.
71.华军益,刘艳,王坤根,等.冠心病痰瘀辨证与血清炎症因子关系的临床研究[J].医学研究杂志,2008,37(3)：112-114.
72.尹克春,罗翌,曾星.冠心病血瘀证病人血白细胞CD11b/CD18表达的研究[J].中西医结合心脑血管病杂志,2003,1(7)：381-382.
73.毛以林,袁肇凯,黄献平,等.冠心病血瘀证与血小板颗粒膜蛋白和纤溶功能关系的探讨[J].湖南中医学院学报,2004,24(3)：29-30.
74.毛以林.冠心病血瘀证证候实质研究进展[J].中国中医药信息杂志,2002.9(10)：45-46.
75.吕中,祝光礼.冠心病血瘀证血浆纤溶活性改变及其与血脂水平的相关性研究[J].中国中医药科技,2009,16(6)：425-426.
76.吕中,祝光礼,施赛珠.冠心病患者单核细胞凝血／纤溶活性改变与证型关系[J].浙江中医杂志,2001,1：34-35.
77.孙红艳,安冬青,宋刚.冠心病秽浊痰阻证与血浆t-PA、 PAI-1及Fib的相关性研究[J].中西医结合心脑血管病杂志,2009,7(4)：389-391.
78.李定祥,杨军辉,邓奕辉.冠心病血瘀证各亚型与纤溶系统活性相关性探讨[J].中国中医药现代远程教育,2007,5(5)：8-10.
79.袁肇凯,黄献平,简维雄,等.冠心病辨证与血凝纤溶系统关系的临床研究[J].云南中医学院学报,2009,32(3)：1-3.
80.方建伟,黄源鹏,林求诚,等.冠心病中医证型与血浆ET、 TXA2-PGI2的关系[J].实用中医药杂志,2005,21(9)：519.
81.杨军辉,张秋雁,李定样,等.冠心病心绞痛中医辨证分型与NO. ET关系的探讨[J].世界中西医结合杂志,2006,1(3)：158-159.
82.张继红,苗志林,刘冬梅,等.冠心病中医证型与血管内皮功能指标的相关性分析[J].心血管康复医学杂志,2006,15(2)：186-187.
83.袁肇凯,黄献平,谭光波,等.冠心病血瘀证血管内皮细胞功能的检测分析[J].中国中西医结合杂志,2006,26(5)：407-460.
84.柏正平,谭光波,卜献春,等.冠心病中医辨证分型与细胞黏附分子的关系[J].中西医结合心脑血管病杂志,2006,4(2)：108-109.
85.杨丁友,段学忠.冠心病心虚证不同证型与血小板活化分子CD62P及CD63表达的关系[J].中国中医药科技,2001,8(5)：293.
86.王云龙,安冬青,朱萌,等.冠心病秽浊痰阻证与血管性血友病因子的相关性研究[J].中西医结合心脑血管病杂志,2009,7(4)：393-394.
87.骆丽娟,顾仁樾.冠心病证型与P-选择素TXB2、6-Keto-PGF1α含量变化关系的研究[J].上海中医药杂志,2002,36(7)：13-14.
88.林桂永,王子健.冠心病血瘀证气血辨证与内皮细胞损伤的关系[J].中西医结合心脑血管病杂志,2005,3(10)：856-858.
89.陈昕琳,项志兵,顾仁樾.vWF、Ps水平与冠心病中医证型相关性的临床研究[J].湖北中医杂志,2007,29(8)：11-13.
90.沈庆乐,张存琪.血瘀证冠心病的GMP-140、 VWF和NO的变化及临床意义[J].现代中西医结合杂志,2000,9(19)：1855-1856.
91.梁知,项志兵,顾仁樾.冠心病中医证型与P-选择素相关性的临床研究[J].辽宁中医杂志,2006,33(12)：1595-1596.
92.梁知,项志兵,顾仁樾.血管性血友病因子、血栓素B2及6-酮-前列环素与冠心病中医证型相关性的临床研究[J].上海中医药杂志,2006,40(6)：13-14.
93.唐巍,遇红,李江涛.冠心病患者血中胰岛素、胰高血糖素与中医证候类型关系的研究[J].中国中医基础医学杂志,2002,8(9)：53-55.
94.张继东,乔云,武传龙,等.冠心病患者胰岛素抵抗与中医辨证分型及纤溶系统活性的相关性研究[J].中国中西医结合杂志,2004,24(5)：408-410.
95.陈晓虎,徐顺娟.冠心病(胸痹)胰岛素抵抗与中医辨证分型关系的临床研究[J].南京中医药大学学报,2006,22(5)：296-298.
96.毛威,叶武,刘强,等.冠心病中医辨证分型与胰岛素抵抗关系的初步研究[J].中国中西医结合杂志,2001,21(9)：657-659.
97.于顾然,贺燕勤,郭云庚,等.冠心病中医证型与胰岛素抵抗、脂质及RBC膜ATP酶关系的研究[J].中医杂志,2002,41(2)：111.
98.赵亚莉,杨幼新.冠心病心电图与中医辨证分型的关系[J].江苏中医,2001,22(9)：20.
99.谢慧文.冠心病患者QT及JT间期离散度与中医证型关系初探[J].中国中医药科技,2000,7(6)：355.
100.谢慧文,张伟,孙敬和.冠心病中医证型与心电图QRS波群离散度的关系[J].上海中医药大学学报,2007,21(2)：31-33.
101.田松.冠心病心电图变化与中医辨证分型的相关性研究[J].中医药临床杂志,2006,18(4)：333-334.
102.尚玉红,洪秀芳,吴鹏,等.冠心病中医辨证与QT和JT离散度的关系[J].中国中西医结合急救杂志,2005,12(2)：87-90.
103.杜延海,朱明军,程江涛,等.冠心病中医证型与心电信息相关性的初步认识[J].中西医结合心脑血管病杂志,2006,(14)：8-9.
104.梁杰.冠心病心律失常与中医辨证分型关系[J].河南医药信息,2001,9(16)：30-31.
105.刘革命,熊尚全,俞爱华.冠心病辨证分型与心律变异性内在关系的研究[J].中医药学刊,2003,21(7)：1153-1154.
106.周劲松.冠心病中医证型与心率变异性关系的研究[J].中国中医急症,2007,17(6)：688.
107.陈少芳,黄海.冠心病中医证型与心室舒张功能的相关性研究[J].福建中医学院学报,2006,16(4)：15-16..
108.丁邦晗,周珂,李俊,等.305例胸痹心痛患者超声心动图改变及其与中医证型的关系[J].中国中医药信息杂志,2008,15(1)：19-21.
109.姜洪茹,郭勇.超声评价左心室收缩功能与冠心病实证者辨证分型关系初探[J].中国医药导报,2007,4(14)：20-21..
110.陈伯钧,张文清,张敏州.冠心病中医分型与心律失常及心功能关系分析[J]..现代中 西医结合杂志,2000,9(19)：1857-1858.
111.李越华,肖沪生.冠心病中医辨证分型与心功能及血液流变学之间关系的研究[J].辽宁中医杂志,2004,31(12)：998-999.
112.张丽萍,张向力,唐巍.冠心病中医辨证分型与左心功能关系的临床研究[J].中国中医药信息杂志,2001,8(7)：50-51.
113.王玉燕,杜武勋,魏营,等.冠心病不同证型与颈动脉内-中膜厚度关系的研究[J].山西中医,2009,25(2)：34-36.
114.张鹏,徐伟建.中医证型与冠状动脉病变程度的相关性研究[J].中西医结合心脑血管病杂志[J].2007,5(2)：101-103.
115.张广增,贺福田,吴范武,等.415例胸痹心痛患者冠状动脉造影结果分析[J].四川中医,2006,24(3)：25-27
116.马晓昌,尹太英,陈可冀,等.冠心病中医辨证分型与冠状动脉造影所见相关性比较研究[J].中国中西医结合杂志,2001,21(9)：654-656.
117.李俊,李小敏,刘映峰,等.冠心病冠状动脉造影结果与中医证型及血脂、脂蛋白关系的研究[J].中国中医急症,2000,9(3)：123-124.
118.李俊,李小敏,刘映峰,等.冠脉狭窄程度与血脂脂蛋白及中医证型关系[J].辽宁中医杂志,1999,26(11)：486-487.
119.严卉,胡晓晟,陈君柱,等.血浆同型半胱氨酸和冠状动脉粥样硬化严重程度与中医证型的关系[J].中国中西医结合杂志,2002,22(11)：813-815.
120.张继红,苗志林,刘冬梅,等.沈阳城区冠心病患者中医证型流行病学特征调查[J].中医药学刊,2006,24(4)：704-706.
121.王阶,何庆勇,马长生,等.基于冠脉造影的冠心病冠脉病变与血瘀证的相关性研究[J].中国中西医结合杂志,2008,25(12)：1074-1077.
122.牛纪华,刘新宇,张建忠,等.冠心病患者冠状动脉影像学与辨证分型相关性因素分析[J].山东中医杂志,2009,28(1)：19-20.
123.王振裕,时亮,陈嘉兴,等.冠心病患者中医证候与冠状动脉造影相关性研究[J].中华中医药杂志,2009,24(9)：1194-1196.
124.李静,张继东,刘同涛.冠心病中医证型与冠脉病变的相关性[J].山东中医药大学学报,2006,30(2)：124-126.
125.刘永明,蒋梅先.259例冠心病患者中医辨证分型与冠脉造影结果的关系研究[J].北京中医,2005,24(3)：131-133.
126.丁邦晗,马长生,张敏州.胸痹心痛患者375例的冠脉病变程度及证型分析[J].中医药学刊,2004,22(6)：1096-1097.
127.尹克春,周文斌,李显生,等.选择性冠状动脉造影与冠心病中医证型的关系[J].中西医结合心脑血管病杂志,2004,2(10)：559-560.
128.刘华峰,程伟,李玉红.冠心病患者中医证型与冠状动脉Gensini积分、病变支数的相关性研究[J].湖北中医学院学报,2006,8(2)：10-12.
129.郭力恒,张敏州,曾影红.岭南地区207例胸痹患者冠脉造影结果与舌象关系分析[J].辽宁中医杂志,2006,33(9)：1098-1099.
130.张敏州,丁邦晗,张维东,等.375例胸痹心痛患者冠状动脉造影结果与中医证型的对比研究[J].中国中西医结合急救杂志,2004,11(2)：115-117.
131.吴焕林,阮新民,杨小波,等.319例冠心病患者证候分布规律分析[J].中西医结合杂志,2007,27(6:)498-500.
132.王阶,刑雁伟,李志忠,等.102例冠心病心绞痛患者中医证候特征分析[J].中医杂志,2007,48(2)：160-162.
133.李晟,程丑夫,陈晓阳.冠脉造影与冠心病心绞痛中医证型的关系研究[J].湖南中医杂志,2007,23(3)：4-6.
134.孙云霞,唐蜀华.冠心病冠状动脉造影188例与中医证型及脂蛋白的相关性分析[J].中华临床医学荟莘杂志,2004,1(2)38-39.
135.邢雁伟,李尊,王阶,等.冠脉病变特征和中医证候要素关系的研究[J].辽宁中医杂志,2008,35(1)：36-38.
136.王阶,李军,姚魁武,等.冠心病心绞痛证候要素和冠脉病变的Logistic回归分析[J].辽宁中医杂志,2007,34(9)：1209-1211.
137.洪敏,李新梅,朱桂平,等.糖尿病冠心病本虚标实证与冠脉病变程度相关性研究[J].广州中医药大学学报,2007,24(1)：33-36.
138.陈伯钧,丁邦晗,张敏州.375例胸痹心痛患者临床证型的回归分析[J].江苏中医药,2005,26(6)：11-13.
139.尹克春,周文斌,陈力,等.89例冠状动脉造影与冠心病中医证型相关性研究[J].中医研究,2005,18(4)：25-26.
140.张志斌,王永炎.证候名称及分类研究的回顾与假设的提出[J].北京中医药大学学报,2003,26(2)：1-5.
1. 陶寿淇,武阳丰,主编.医疗卫生人员心血管病防治知识.北京：中国友谊出版公司,2000.
2.中华医学会心血管病分会,中华心血管病杂志编辑委员会.不稳定性心绞痛的诊断和治疗建议[J].中华心血管病杂志,2000,28(6)：409-412.
3. 邢雁伟.冠心病心绞痛证候要素诊断标准及和理化检查关系研究：[博士后出站报告].北京：中国中医科学院,2007.
4. Spertus JA, Winder JA, Dewhurst TA, et al. Development and validation of the Seattle Angina Questionnaire:a new function status measure for coronary artery disease. J Am Coil Cardiol,1995,25:333-34.
1.黄建平,张新霞,李松.心电图与冠状动脉造影诊断冠心病的评价[J].中国现代医学杂志,2005,15(10)：1529.
2.林荣,郭继鸿.心血管疾病的现代观点[M].北京：北京大学医学出版社,2005：82-99.
3.Libby P, Ridker PM.Novel inflammatory markers of coronary risk.Theory versus practice[J]. Circulation,1999,100:1148-1150.
4. Ross R.Atherosclerosis-an inflammatory disease[J].N Engl J Med,1999,340:115-126.
5. Libby P, Ridker PM, Maseri A. Inflamation and atherosclerosis[J]. Circulation,2002,105: 1135-1143.
6. Libby P.Atherosclerosis the new view[J]. Sci Am,2002,286:46-55.
7. Asano H, Sone T, Tsuboi H, et al.Diagnosis of right ventricular infarction by overlap images of simultaneous dual emission computed tomography using technetium-99 pyrophosphate and thalium-201[J].Am J Cardiol,1993,71:902908.
8. Stampfer MJ,Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians[J]JAM A,1992,268:877-881.
9.Boushey CJ,Beresford SA,Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes [J]. JAMA,1995,274:1049-1057.
10. Refsum H,Ueland PM,Nygard O, et al. Homocysteine and cardiovascular disease [J]. Ann Rev Med,1998,49:31-62.
11.Verhoef P,Kok FJ,Kruyssen DA, et al. Plasma total homocysteine,B vitamins,and risk of coronary atherosclerosis[J].Arterioscler Thromb Vasc Riol,1997,17:989-995.
12.Visaecs MCM,' Ihomas C. Hypochlorous acid disrupts the adhesive properties of subendothelial matrix[J]. Free Radic Biol Med,1997,23:401-411.
13. Hazen SL.Myeloperoxidase and plaque vulnerability,arterioscler,thromb[J]. Vasc Biol, 2004,24:1143-6.
14. Heinecke W,Daehnke HL Oxidants and antioxidants in the pathogenesis of atherosclerosis: implication for the oxidized low density lipoprotein hypothesis[J]. Atherosclerosis,1998, 14:1-15.
15. Brian J,O'Connell, Jacques Genest.High-density lipoproteins and endothelial function [J]. Circulation,2001,104-1978-83.
16.Johnson JL,Fritsche-Danielson R,Behrendt M, et al.Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability[J].Cardiovasc Res,2006, 71(3):586-595.
17. Papalambros E,Sigala F,Georgopoulos S, et al.Vascular endothelial growth factor and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with plaqued estabilization via neovascularization[J].Cerebrovasc Dis,2004, 18(2):160-165.
18. Chen F,Eriksson P,Hansson GK, et al.Expression of matrix metalloproteinase 9 and its regulators in the unstable coronaryatherosclerotic plaque[J].Int J Mol Med,2005,15 (1):57-65
19. Arno QKaski JC,Smith DA, et al.Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques[J]. Heart,2005,91(4):521-525.
20. Toyo-Oka T,Aizawa T,Suzuki N, et al. Increased plasma level of endothelinl and coronary spasm induction in patients with vasospastic angina pectoris. Circulation,1991,83:476-483.
21. Artigou JY,Salloum J,Carayon A, et al. Variations in plasma endothelin concentrations during coronary spasm. Eur Heart J,1993,14:780-784.
22. Kaski JC, Cox ID, Crook JR, et al. Differential plasma endothelin levels in subgroups of patients with angina and angiographically normal coronary arteries. Am Heart J,1998,136 (3):412-417.
23. De Lemon IA, Marrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes[J]. N Engl J Med, 2001,345:1014-1021.
24. Morrow DA, de Lemoe JA, Sebatine MS, et al.Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST elevation myocardial infarction;B-type natriuretic peptide and prognosis in TACTICS-TIMI 18[J]. J Am Coll Cardiol,2003, 41:1264-1272.
25.Campbell DJ,Munir V,Hennessy OF, et al.Plasma amino-terminal pro-brain natriuretic peptide levels in subjects presenting to the Emergeney Department with suspeeted acute coronary syndrome:possible role in seleeting patients for follow up? [J].Intern Med J, 2001,31:211-219.
26. Zimmerman GA,McIntyre TM,Prescott SM, et al. The platelet-acativating factor signaling system and its regulators in syndromes of inflammaiton and thrombosis[J]. Crit Care Med. 2002,30(5 Suppl):s294-301.
27. Louis NA,Hamilton KE,Colsan SP.Lipid mediator networks and leukocyte transmigration [J].Prostaglandins Leukot Essent Fatty Acids,2005,73(3-4):197-202.
28. NinioE. Phospholipid mediators in the vessel wall:involvement in atherosclerosis [J].Curr Opin Clin Nutr Metab Care,2005,8(2):123-131.
29. Carter AM. Inlfammation, thrombosis and acute coronary syndromes[J]. Diab VascDis Rse,2005,2(3):113-121.
30.Gum P A, Kottke-Marchant K, Poggio E D,et al.Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J].Am J Cardiol,2001,88:230-235.
31.徐成斌.血脂异常的药物治疗新进展[J].中华心血管病杂志,2001,29：189.
32.Wilsom PW. Assessing coronary heart disease risk with traditional and novel risk factors [J].Clin Cardiol,2004,27(6Suppl3):1117.
33.Lukkarinen H, Hentinen M, Assessment of quality of life with the Nottingham Health Profile among women with coronary artery disease[J]. Heart Lung,1998,27:189-199.
34.邢文华,陈晓敏,朱建华.SF-8简短量表用于冠心病病人健康相关生活质量测定的可行性[J].国外医学心血管疾病分册,2004,31(3)：181-184.
35.刘同想,孔索平,廖忠友,等.西雅图心绞痛调查量表对冠心病患者机体功能及生活质量的评估研究[J].中国行为医学科学,1997,6(2)：127-129.
36.李静,常改.西雅图量表测量冠心病患者生活质量的评价[J].中国公共卫生,2004,5(5)：594.
37.郭卉.血府逐瘀胶囊对不稳定心绞痛患者CRP、 BNP的影响[J].天津中医药,2009,26(3)：209-210.
38.张玲端,任幼红.血府逐瘀汤对气滞血瘀型CHD血浆HCY LDL-C水平的影响[J].辽 宁中医药大学学报,2009,11(6)：108-109.
39.王宝祥,董雪梅,郭爱民,等.血府逐瘀汤对不稳定型心绞痛患者血管内皮功能的影响[J].中西医结合学报,2006,4(3)：256-258.
2.耿晓娟,张军平.试论病证结合、方证对应与辨证论治[J].中医杂志,2008,49(9)：775-777.
3.姚魁武,王阶,朱翠玲,等.不同疾病血瘀证量化诊断的比较研究[J].辽宁中医杂志,2006,33(11)：1381-1382.
4.邢雁伟,王阶,姚魁武,等.对1022例血瘀证患者基于对应相关方法的客观量化研究[J].北京中医大学学报,2007,30(8)：556-559.
5.衷敬柏,王阶,赵宜军,等.病证结合与方证相应研究[J].辽宁中医杂志,2006,33(2)：137-139.
6.杜武勋.关于中西医结合证病结合的疾病诊断思维模式探讨[J].天津中医学院学报,2002,21(2)：12-13.
7.李敬林,王太一,王禄增,等.2型糖尿病证病结合动物模型的研究[J].中国比较医学杂志,2007,17(8)：473-475.
8.孙广仁,王洪武,高博,等.COPD寒饮蕴肺证大鼠病证结合模型的建立[J].山东中医药大学学报,2007,31(3)：242-244.
9.刘丽梅,陈琳,王瑞海,等.病证结合方证相应基础研究的现状[J].中国中医基础医学杂志,2009,15(5)：334-336.
10.谢元华,张京春,陈可冀.病证方药相应及其意义[J].中西医结合心脑血管病杂志,2008,6(1)：1-2.
11.陈可冀,宋军.病证结合的临床研究是中西医结合研究的重要模式[J].继续医学教育,2007,21(19)：12-15.
12.朱邦贤.“方证相对”是中医辨证论治法则乏魂[J].上海中医药杂志,2006,40(8)：52-54.
13.李瑞,尹英杰,林殷,鲁兆麟.中医方证客观化研究初探[J].北京中医药大学学报,2002,25(3)：6-11.
14.金海浩.中医学的方证相应论[J].黑龙江中医药,2005,1：44-46.
15.谢鸣.“方证相关”逻辑命题及其意义[J].北京中医药大学学报,2003,3(26)：11-12.
16.沈自尹.有关证与神经内分泌免疫网络的研究[J].中医药学刊,2003,21(1)：10-14.
17.王学良,李赛美.方证规范化研究的意义及方法探讨[J].广州中医药大学学报,2009,26(1)：83-85.
18.王玉川.关于“有是证、用是方”的反思[J].北京中医药大学学报,1998,21(6)：2-4.
19.贾春华,王永炎,黄启福,等.以方测证法不可行论[J].辽宁中医杂志,2006,33(12)：1549-1550.
20.陈云慧,王燕,张昱,等.基于贝叶斯方法的方证相应研究[J].辽宁中医杂志,2008,35(3)：360-362.
21.吴昊,李书琴,董记华.基于粗糙集理论的中医方证相关性分析模型的研究[J].现代电子技术,2007(24)：75-78.
22.叶任高,陆再英.内科学.第6版.北京：人民卫生出版社,2004.
23.邵念方,骆丰,许荣廷.冠心病中西医综合治疗.北京：人民卫生出版社,2004.
24.Rosenson RS, Tangney CC. Antiatherothromboic properties of stains. ImPlication for cardiovascular event reduction[J]. JAMA,1998,279:1643-1650.
25.NaghaviM, Libbyp, Falk E, et al.From vulnerable plaque to vulnerable patient.A call for new definition and risk assessment strategies [J]. Part1.Circulation,2003,108:1664-1672.
26.张长群.不稳定型心绞痛的诊断和治疗[J].现代医药卫生,2005,21(15)：1986-1987.
1.郭蕾,王永炎,张志斌.证候概念的诠释[J].北京中医药大学学报,2003,22(2)：5.
2.王永炎.完善中医辨证方法体系的建议[J].中医杂志,2004,45(10)：729.
3.黄东平.中医古籍对心力衰竭的论述探要[J].中医药学刊,2003,21(4)：592-593.
4.杨培君,杨磊.充血性心力衰竭的中医证治概要[J].陕西中医学院学报,2002,25(1)：2-5.
5.黄东平,罗懿明,黄衍寿,等.充血性心力衰竭中医证型及其演变规律的临床观察[J].中西医结合心脑血管病杂志,2003,1(12)：685-686.
6.于涛,曹洪欣.胸痹(冠心病)病机演变探微[J].中医药信息,2004,21(4)：1-2.
7.韩丽萍,刘实.骨质疏松症中医证候的演变规律[J].中华中医药学刊,2008,26(12)：2601-2602.
8.吕维柏.艾滋病中西医防治学[M].北京：人民卫生出版社,1994：144.
9.杨凤珍.HIV/AIDS中医分期辨证治疗[J].中国医学报,2004,19(4)：240-242.
10.陈江.溃疡性结肠炎中医病机演变及证治探讨[J].新中医,2005,37(4)：11-12.
11.周俊元.常见急腹症的演变规律及辨证施治研究[J].中医杂志,1986,1：59-62.
12.窦志芳,郭蕾,张俊龙,等.中风病证候动态时空特征研究的思考[J].中西医结合,脑血管病杂志,2006,4(2)：139-140.
13.岑玉文.HIV/AIDS中医证型、证型演变及其与T淋巴细胞活化关系的研究观察：[博士学位论文].广州：广州中医药大学,2008.
14.刘渊,安莉萍.骨关节病中医证型分布及演变规律的研究[J].现代中西医结合杂志,2008,17(13)：1950-1951.
15.聂峰.慢性肾衰竭辨证规范化及中医证候规律的研究：[硕士学位论文].广州：第一军医大学,2005.
16.刘恩顺,孙增涛,封继宏,等.天津市支气管哮喘证候分布及演变规律的临床流行病学调查[J].辽宁中医药大学学报,2008,10(9)：126-127.
17.陈霞.肠易激综合征的证候演变规律研究：[硕士学位论文].成都：成都中医药大学,2003.
18.刘绍能,陶夏平,王融冰,等.慢性乙型肝炎中医证候演变规律研究[J].中国中医药科技,2008,15(3)：161-163.
19.唐智敏,辛伟,瞿晓东,等.肝硬化肝功储备力与中医证型演变的关系[J].中西医结 合肝病杂志,1993,3(4)：5-7.
20.张广中,王萍,王莒生,等.2651例寻常型银屑病中医证候分布和演变规律研究[J].中医杂志,2008,49(10)：894-895.
21.张磊,张光华,刘文涛,等.胃院痛证候的演变规律[J].成都中医药大学学报,1995,18(4)：19-22.
22.任宏义,和贵童,张玉枝.脾虚证证型演变规律的探讨-508例慢性萎缩性胃炎的临床病理分析[J].山东中医学院学报,1992,16(4)：43-36.
23.张明雪,曹洪欣,常艳鹏.冠心病(稳定性心绞痛)证候演变规律研究[J].中华中医药杂志,2010,25(1)：24-27.
24.薛增明,李长生,宁美芳,等.42例冠心病患者冠状动脉支架植入术前后中医证型的演变[J].山东中医杂志,2005,24(12)：719-720.
25.高婷.90例慢性肾衰竭并肾性骨病的证候演变规律初探：[硕士学位论文].湖北：湖北中医学院,2006.
26.孙舒敏.中晚期原发性非小细胞肺癌化疗前后中医证候演变规律探讨：[硕士学位论文].北京：北京中医药大学,2008.
27.黄建龙,李云辉,林中平,等.120例重型颅脑损伤急性期中医证型及演变规律临床研究[J].中医研究,2005,18(9)：19-22.
28.曾普华, 刘伟胜, 潘敏求,等.原发性肝癌围血管介入期中医证候演变规律初探[J].湖南中医药大学学报,2008,28(3)：54-56.
29.袁芳.鼻咽癌放疗前、中、后的证型分布及其演变规律的研究：[硕士学位论文].广州：广州中医药大学,2007.
30.范洪,侯英荣,郑晓丽,等.163例细菌感染性呼吸系统疾病的中医证型演变规律研究[J].中医研究,2006,19(2)：24-26.
31.范洪,侯英荣,兰洪英.呼吸系统真菌感染中医证型演变规律的研究[J].世界中西医结合杂志,2008,3(1)：39-40.
32.王雪峰,董丹,虞坚尔,等.小儿肺炎中医证候演变规律研究[J].中医杂志,2005,46(5)：374-376.
33.王雪峰,董丹,虞坚尔,等.儿童肺炎常见病原学分析及中医证候演变规律的多中心随机双盲安慰剂对照试验研究[J].中国循证儿科杂志,2006,1(3)：170-176.
34.吕玉霞,杜艳玲,董彩风,等.小儿肺炎中医证候分布特点及证型演变特点的临床研究[J].中医儿科杂志,2008,4(3)：13-17.
35.谢颖桢,邹忆怀,马洪明,等.中风病急性期中经络和中脏腑证候要素的动态比较[J].中国中医基础医学杂志,2006,12(10)：746-748.
36.马斌,高颖.中风病发病第7天证候要素的初步分析[J].中国中医基础医学杂志,2006,12(07)：494-496.
37.刘强,高颖.中风病不同阶段四诊信息的指标聚类分析[J].中华中医药杂志,2007,22(3)：162-164.
38.马斌,高颖.中风病发病第7天和第14天证候要素演变规律初步研究[J].辽宁中医杂志,2006,33(12)：1561-1563.
39.马斌,高颖.中风病恢复期证候要素的研究[J].江苏中医药,2007,39(01)：27-29.
40.薛晓琳.慢性疲劳综合征的症证特征、演变及预后转归规律的初步研究：[硕士学位论文].北京：北京中医药大学,2003.
41.高坤,孙伟,周栋,等.慢性肾脏病中医证型分布及演变规律研究[J].江苏中医药,2008,40(6)：33-35.
42.李同侠.慢性肾衰肾性骨病中医证候分布特征及演变的研究：[硕士学位论文].北京：中国中医科学院,2006.
1.1980年全国冠心病辨证论治研究座谈会.冠心病中医辨证试行标准[J].中医杂志,1980,21(8)：46.
2.陈贵延,薛赛琴,最新国内外疾病诊疗标准[M].第1版.北京：学苑出版社1992：209-212,678-686.
3.中西医结合学会心血管专业委员会.冠心病中医辨证标准[J].中西医结合杂志,1991,11(5)：257.
4.中华人民共和国卫生部.中药新药临床研究指导原则：第1辑[S].1993：41.
5.国家中医药管理局·中医病证诊断疗效标准[S].南京：南京大学出版社,1994：18-19.
6.郑筱萸.中药新药临床研究指导原则(试行)[M].北京：中国医药科技出版社,2002：68-73.
7.王永炎主编.中医内科学[M].上海：上海科学技术出版社,1997.
8.谭日强.冠心病的辨证分型论治[J].湖南中医学院学报,1986,1：17-19.
9.陶克文.胸痹心痛证治体会[J].实用中医药杂志,1994,(3)：3.
10.沈绍功.诊治冠心病的新思路[J].中国中医急症,1999,8(2)：51.
11周文泉.冠心病心绞痛辨证论治研究进展[J].新中医,1980,12(5)：43.
12.王鹏.冠心病心绞痛辨证论治研究的现状及分析[J].中国中医药信息杂志,1997,4(5)：23-24.
13.宋秀明.王左治疗冠心病的经脸.湖北中医杂志,1999,21(5)：197.
14.李幼勋,王德华.胸痹的病因病机及其证治述略[J].实用中医内科杂志,2002,16(4)：184-1857.
15.王文革,姚红芳.冠心病心绞痛的中医辨证分析[J].中西医结合心脑血管病杂志,2004,2(12)：730.
16.胡东斐.胸痹证治文献研究[J].山东中医药大学学报,2005,29(1)：37-40.
17.郭志华.冠心病心绞痛2432例中医辨证分型综合统计分析[J].湖南中医杂志,1998,14(2)：7-8.
18.旷惠桃,潘远根.冠心病心绞痛临床证型分类探讨[J].中医杂志,1997,38(12)：742.
19.衷敬柏,董绍英,王阶,等.2689例冠心病心绞痛证候要素的文献统计分析[J].中国中医药信息杂志,2006,13(5)：100-101.
20.张琳,于鑫婷,徐浩.冠心病中医证候特点的分析与思考[J].中西医结合心脑血管病杂志,2009,7(5)：578-580.
21.张秋雁,邓冰湘.冠心病心绞痛临床中医证型分布的回顾性分析[J].中医研究,2005,18(11)：23-24.
22.李军,王阶.冠心病心绞痛证候要素与应证组合的5099例文献病例分析[J].中国中医基础医学杂志,2007,13(12)：926-927.
23.晏峻峰,朱文锋.粗糙集理论在中医证素辨证研究中的应用[J].中国中医基础医学杂志,2006,12(2)：90-93.
24.马静娴.冠心病心绞痛辨证施治疗效观察[J].黑龙江中医药,1991,(2)：13.
25.王永霞,胡宇才,朱明军,等.冠心病心绞痛中医证候分布相关性研究[J].世界中西医结合杂志,2008,39(12)：714-716.
26.刘德桓,许真真,郭伟聪.冠心病心绞痛395例中医证型特点探讨[J].中医杂志,1995,36(10)：617-618.
27.郝惠莉,王明亮.辨证分型治疗冠心病心绞痛172例[J].浙江中医杂志,1996,31(1)：13.
28.黄腾蛟,嵇美霞,史大卓.111例冠心病中医辨证分型研究[J].现代中西医结合杂志,2004,13(2)：172.
29.吴辉,于扬文,吴伟,等.116例冠心病患者中医证候及病因分析[J].江苏中医药,2004,25(10)：30-31.
30.何庆勇,王阶,姚魁武,等.1069例冠心病脏腑虚证的多中心前瞻性研究[J].中华中医药杂志,2009,24(1)：31-33.
31.韦湘林.135例冠心病的中医证型及舌脉象分析[J].新中医,1996,1：8-10.
32.姚笛,王忆勤,李福凤,等.187例冠心病病例临床证型观察[J].辽宁中医杂志,2009,36(6)：930-933.
33.李晋宏.213例冠心病中医辨证分型研究[J].陕西中医,2006,27(2)：149-150.
34.王阶,李军,姚魁武,等.冠心病心绞痛证候要素与应证组合研究[J].中医杂志,2007,48(10)：920-922.
35.董国菊,刘剑刚,王承龙,等.300例冠心病患者中医证型分布特点分析[J].环球中医药,2009,2(2)：96-98.
36.吴焕林,阮新民,杨小波,等.319例冠心病患者证候分布规律分析[J].中国中西医结合杂志,2007,27(6)：498-500.
37.石刚,刘婷,程丑夫.冠心病常见证候临床流行病学调查[J].中华中医药学刊,2007,25(8)：1675-1676.
38.吴肠,王轩,崔杰,等.348例冠心病患者中医证候特点因子分析[J].中华中医药学刊,2009,27(2)：392-394.
39.刘永家.382例冠心病中医证型分布与病因关系[J].辽宁中医学院学报,2000,2(4)：245.
40.贾振华,王永军,吴以岭,等.基于熵的复杂系统分划方法与冠心病心绞痛证候要素提取及其分布规律[J].第二军医大学学报,2007,28(7)：775-777.
41.邢雁伟,王阶,衷敬柏,等.采用聚类分析和对应相关方法研究1069例冠心病心绞痛证候应证组合规律[J].中华中医药杂志,2007,22(11)：747-750.
42.周中山.冠心病心绞痛中医证型与血液流变学的相关性研究[J].湖南中医药导报,2001,7(7)：360-361.
43.陈炳旺,蔺德明.冠心病中医实证血液流变学变化的临床研究[J].福建中医学院学报,2000,10(1)：1-3.
44.吕芳芳,黄文.冠心病心绞痛不同证型与血液流变关系的探讨[J].北京中医,2004,23(6)：327-328.
45.丘瑞香,罗致强,朱雅宣,等.冠心病血瘀证血液理化特性与中医证型相关性研究.中医杂志,2002,43(5)：378-379.
46.王桂玲,王磊,王忠爱,等.冠心病的中医辨证分型与血液流变学指标的关系[J].实用心电学杂志,2007,16(2)：124-125.
47.刘辛光.冠心病辨证分型与血液动力学流变学变化关系探析[J].辽宁中医杂志,2005, 32(10)：991.
48.陈宝珍,胡志希,袁肇凯,等.53例早发冠心病心血瘀阻证甲襞微循环的检测分析[J].中西医结合心脑血管病杂志,2007,5(9)：803-804.
49.郭平清,林求诚,郭银庚,等.冠心病肾阳虚证血脂特点.浙江中西医结合杂志,2003,13(4)：208-2-10.
50.谢海波,陈新宇,石刚,等.冠心病心绞痛中医证型与C反应蛋白血脂的相关性研究[J].湖南中医学院学报,2005,25(4)：32-34.
51.其其格,王伟,毕力夫,等.冠心病血瘀证与血脂血尿酸关系的探讨[J].辽宁中医杂志,2008,35(12)：1826-1827.
52.邓奕辉,李定祥,杨军辉.冠心病心绞痛血瘀证四亚型与血脂的相关性研究[J].湖南中医杂志,2008,24(1)：59；100.
53.袁肇凯,田松,黄献平,等.冠心病痰瘀证候血脂指标的Meta分析[J].云南中医学院学报,2008,31(5)：1-3.
54.冉旭,林凯旋,安辉,等.冠心病的中医辨证分型与同型半胱氨酸的相关性研究[J].中西医结合心脑血管病杂志,2007,5(8)：750-751.
55.林凯旋,安辉,缪灿铭,等.冠心病血瘀证与同型半胱氨酸的相关性研究[J].中医研究,2007,20(2)：32-33.
56.严卉,胡晓晟,陈君柱,等.血浆同型半胱氨酸和冠状动脉粥样硬化严重程度与中医证型的关系[J].中国中西医结合杂志,2002,22(11)：813-816.
57.卢玉俊,石磊.冠心病中医证型与血浆同型半胱氨酸水平相关性的研究[J].浙江中医药大学学报,2009,33(1)：103-104.
58.方显明,唐耀平,郑德俊.冠心病血浆同型半胧氨酸与中医证型的相关性[J].中医杂志2005,46(10)：775-776.
59.孔丽君.冠心病患者血浆同型半胱氨酸水平与辨证分型相关性研究[J].实用中西医结合临床,2004,4(1)：7-8.
60.李超,安冬青,王娟,等.冠心病秽浊痰阻证与血浆同型半胱氨酸的相关性研究[J].中西医结合心脑血管病杂志,2008,6(4)：384-385.
61.商秀洋,石洁.冠心病中医辨证与血清高敏C反应蛋白的关系研究[J].现代中西医结合杂志,2008,17(6)：818-819.
62.王强,黄绍湘,刘钧超,等.冠心病血瘀证与超敏c-反应蛋白关系的临床探讨[J].广西中医药,2005,28(3)：7-8.
63.林超,郭进建,林青,等.高敏c反应蛋白与不稳定型心绞痛中医证型相关性研究[J].中国中医急症,2007,16(10)：1221-1223.
64.石刚,刘婷.冠心病及其常见中医证型与超敏c反应蛋白的关系探讨[J].中医药临床杂志,2007,19(1)：29-30.
65.杨徐杭,汶医宁,魏敏慧,等.冠心病中医辨证与血清c反应蛋白的相关性研究[J].中医药学刊,2004,22(9)：1649-1650..
66.杨徐杭,汶医宁,王军威,等.冠心病中医辨证与血清IL-18、 sCD40L的关系[J].江苏中医药,2009,41(3)：41-42.
67.刘艳,叶武,王坤根,等.冠心病痰瘀辨证与相关炎症标志物关系初探[J].中华中医药杂志,2008,23(12)：1121-1124.
68.毛以林,李旭,彭素娟,等.冠心病血瘀证与高敏C-反应蛋白相关性研究[J].中国中医药信息杂志,2007,14(8)：26-27.
69.易自刚,王强,张双旗.急性冠脉综合征中医证型与IL-18. Hs-CRP的相关性研究[J].江苏中医药,2007,39(12)：22-23.
70.郑峰,曲丹,徐浩,等.冠心病稳定期患者中医辨证与超敏C反应蛋白相关性研究[J].中国中西医结合杂志,2009,29(6)485-487.
71.华军益,刘艳,王坤根,等.冠心病痰瘀辨证与血清炎症因子关系的临床研究[J].医学研究杂志,2008,37(3)：112-114.
72.尹克春,罗翌,曾星.冠心病血瘀证病人血白细胞CD11b/CD18表达的研究[J].中西医结合心脑血管病杂志,2003,1(7)：381-382.
73.毛以林,袁肇凯,黄献平,等.冠心病血瘀证与血小板颗粒膜蛋白和纤溶功能关系的探讨[J].湖南中医学院学报,2004,24(3)：29-30.
74.毛以林.冠心病血瘀证证候实质研究进展[J].中国中医药信息杂志,2002.9(10)：45-46.
75.吕中,祝光礼.冠心病血瘀证血浆纤溶活性改变及其与血脂水平的相关性研究[J].中国中医药科技,2009,16(6)：425-426.
76.吕中,祝光礼,施赛珠.冠心病患者单核细胞凝血／纤溶活性改变与证型关系[J].浙江中医杂志,2001,1：34-35.
77.孙红艳,安冬青,宋刚.冠心病秽浊痰阻证与血浆t-PA、 PAI-1及Fib的相关性研究[J].中西医结合心脑血管病杂志,2009,7(4)：389-391.
78.李定祥,杨军辉,邓奕辉.冠心病血瘀证各亚型与纤溶系统活性相关性探讨[J].中国中医药现代远程教育,2007,5(5)：8-10.
79.袁肇凯,黄献平,简维雄,等.冠心病辨证与血凝纤溶系统关系的临床研究[J].云南中医学院学报,2009,32(3)：1-3.
80.方建伟,黄源鹏,林求诚,等.冠心病中医证型与血浆ET、 TXA2-PGI2的关系[J].实用中医药杂志,2005,21(9)：519.
81.杨军辉,张秋雁,李定样,等.冠心病心绞痛中医辨证分型与NO. ET关系的探讨[J].世界中西医结合杂志,2006,1(3)：158-159.
82.张继红,苗志林,刘冬梅,等.冠心病中医证型与血管内皮功能指标的相关性分析[J].心血管康复医学杂志,2006,15(2)：186-187.
83.袁肇凯,黄献平,谭光波,等.冠心病血瘀证血管内皮细胞功能的检测分析[J].中国中西医结合杂志,2006,26(5)：407-460.
84.柏正平,谭光波,卜献春,等.冠心病中医辨证分型与细胞黏附分子的关系[J].中西医结合心脑血管病杂志,2006,4(2)：108-109.
85.杨丁友,段学忠.冠心病心虚证不同证型与血小板活化分子CD62P及CD63表达的关系[J].中国中医药科技,2001,8(5)：293.
86.王云龙,安冬青,朱萌,等.冠心病秽浊痰阻证与血管性血友病因子的相关性研究[J].中西医结合心脑血管病杂志,2009,7(4)：393-394.
87.骆丽娟,顾仁樾.冠心病证型与P-选择素TXB2、6-Keto-PGF1α含量变化关系的研究[J].上海中医药杂志,2002,36(7)：13-14.
88.林桂永,王子健.冠心病血瘀证气血辨证与内皮细胞损伤的关系[J].中西医结合心脑血管病杂志,2005,3(10)：856-858.
89.陈昕琳,项志兵,顾仁樾.vWF、Ps水平与冠心病中医证型相关性的临床研究[J].湖北中医杂志,2007,29(8)：11-13.
90.沈庆乐,张存琪.血瘀证冠心病的GMP-140、 VWF和NO的变化及临床意义[J].现代中西医结合杂志,2000,9(19)：1855-1856.
91.梁知,项志兵,顾仁樾.冠心病中医证型与P-选择素相关性的临床研究[J].辽宁中医杂志,2006,33(12)：1595-1596.
92.梁知,项志兵,顾仁樾.血管性血友病因子、血栓素B2及6-酮-前列环素与冠心病中医证型相关性的临床研究[J].上海中医药杂志,2006,40(6)：13-14.
93.唐巍,遇红,李江涛.冠心病患者血中胰岛素、胰高血糖素与中医证候类型关系的研究[J].中国中医基础医学杂志,2002,8(9)：53-55.
94.张继东,乔云,武传龙,等.冠心病患者胰岛素抵抗与中医辨证分型及纤溶系统活性的相关性研究[J].中国中西医结合杂志,2004,24(5)：408-410.
95.陈晓虎,徐顺娟.冠心病(胸痹)胰岛素抵抗与中医辨证分型关系的临床研究[J].南京中医药大学学报,2006,22(5)：296-298.
96.毛威,叶武,刘强,等.冠心病中医辨证分型与胰岛素抵抗关系的初步研究[J].中国中西医结合杂志,2001,21(9)：657-659.
97.于顾然,贺燕勤,郭云庚,等.冠心病中医证型与胰岛素抵抗、脂质及RBC膜ATP酶关系的研究[J].中医杂志,2002,41(2)：111.
98.赵亚莉,杨幼新.冠心病心电图与中医辨证分型的关系[J].江苏中医,2001,22(9)：20.
99.谢慧文.冠心病患者QT及JT间期离散度与中医证型关系初探[J].中国中医药科技,2000,7(6)：355.
100.谢慧文,张伟,孙敬和.冠心病中医证型与心电图QRS波群离散度的关系[J].上海中医药大学学报,2007,21(2)：31-33.
101.田松.冠心病心电图变化与中医辨证分型的相关性研究[J].中医药临床杂志,2006,18(4)：333-334.
102.尚玉红,洪秀芳,吴鹏,等.冠心病中医辨证与QT和JT离散度的关系[J].中国中西医结合急救杂志,2005,12(2)：87-90.
103.杜延海,朱明军,程江涛,等.冠心病中医证型与心电信息相关性的初步认识[J].中西医结合心脑血管病杂志,2006,(14)：8-9.
104.梁杰.冠心病心律失常与中医辨证分型关系[J].河南医药信息,2001,9(16)：30-31.
105.刘革命,熊尚全,俞爱华.冠心病辨证分型与心律变异性内在关系的研究[J].中医药学刊,2003,21(7)：1153-1154.
106.周劲松.冠心病中医证型与心率变异性关系的研究[J].中国中医急症,2007,17(6)：688.
107.陈少芳,黄海.冠心病中医证型与心室舒张功能的相关性研究[J].福建中医学院学报,2006,16(4)：15-16..
108.丁邦晗,周珂,李俊,等.305例胸痹心痛患者超声心动图改变及其与中医证型的关系[J].中国中医药信息杂志,2008,15(1)：19-21.
109.姜洪茹,郭勇.超声评价左心室收缩功能与冠心病实证者辨证分型关系初探[J].中国医药导报,2007,4(14)：20-21..
110.陈伯钧,张文清,张敏州.冠心病中医分型与心律失常及心功能关系分析[J]..现代中 西医结合杂志,2000,9(19)：1857-1858.
111.李越华,肖沪生.冠心病中医辨证分型与心功能及血液流变学之间关系的研究[J].辽宁中医杂志,2004,31(12)：998-999.
112.张丽萍,张向力,唐巍.冠心病中医辨证分型与左心功能关系的临床研究[J].中国中医药信息杂志,2001,8(7)：50-51.
113.王玉燕,杜武勋,魏营,等.冠心病不同证型与颈动脉内-中膜厚度关系的研究[J].山西中医,2009,25(2)：34-36.
114.张鹏,徐伟建.中医证型与冠状动脉病变程度的相关性研究[J].中西医结合心脑血管病杂志[J].2007,5(2)：101-103.
115.张广增,贺福田,吴范武,等.415例胸痹心痛患者冠状动脉造影结果分析[J].四川中医,2006,24(3)：25-27
116.马晓昌,尹太英,陈可冀,等.冠心病中医辨证分型与冠状动脉造影所见相关性比较研究[J].中国中西医结合杂志,2001,21(9)：654-656.
117.李俊,李小敏,刘映峰,等.冠心病冠状动脉造影结果与中医证型及血脂、脂蛋白关系的研究[J].中国中医急症,2000,9(3)：123-124.
118.李俊,李小敏,刘映峰,等.冠脉狭窄程度与血脂脂蛋白及中医证型关系[J].辽宁中医杂志,1999,26(11)：486-487.
119.严卉,胡晓晟,陈君柱,等.血浆同型半胱氨酸和冠状动脉粥样硬化严重程度与中医证型的关系[J].中国中西医结合杂志,2002,22(11)：813-815.
120.张继红,苗志林,刘冬梅,等.沈阳城区冠心病患者中医证型流行病学特征调查[J].中医药学刊,2006,24(4)：704-706.
121.王阶,何庆勇,马长生,等.基于冠脉造影的冠心病冠脉病变与血瘀证的相关性研究[J].中国中西医结合杂志,2008,25(12)：1074-1077.
122.牛纪华,刘新宇,张建忠,等.冠心病患者冠状动脉影像学与辨证分型相关性因素分析[J].山东中医杂志,2009,28(1)：19-20.
123.王振裕,时亮,陈嘉兴,等.冠心病患者中医证候与冠状动脉造影相关性研究[J].中华中医药杂志,2009,24(9)：1194-1196.
124.李静,张继东,刘同涛.冠心病中医证型与冠脉病变的相关性[J].山东中医药大学学报,2006,30(2)：124-126.
125.刘永明,蒋梅先.259例冠心病患者中医辨证分型与冠脉造影结果的关系研究[J].北京中医,2005,24(3)：131-133.
126.丁邦晗,马长生,张敏州.胸痹心痛患者375例的冠脉病变程度及证型分析[J].中医药学刊,2004,22(6)：1096-1097.
127.尹克春,周文斌,李显生,等.选择性冠状动脉造影与冠心病中医证型的关系[J].中西医结合心脑血管病杂志,2004,2(10)：559-560.
128.刘华峰,程伟,李玉红.冠心病患者中医证型与冠状动脉Gensini积分、病变支数的相关性研究[J].湖北中医学院学报,2006,8(2)：10-12.
129.郭力恒,张敏州,曾影红.岭南地区207例胸痹患者冠脉造影结果与舌象关系分析[J].辽宁中医杂志,2006,33(9)：1098-1099.
130.张敏州,丁邦晗,张维东,等.375例胸痹心痛患者冠状动脉造影结果与中医证型的对比研究[J].中国中西医结合急救杂志,2004,11(2)：115-117.
131.吴焕林,阮新民,杨小波,等.319例冠心病患者证候分布规律分析[J].中西医结合杂志,2007,27(6:)498-500.
132.王阶,刑雁伟,李志忠,等.102例冠心病心绞痛患者中医证候特征分析[J].中医杂志,2007,48(2)：160-162.
133.李晟,程丑夫,陈晓阳.冠脉造影与冠心病心绞痛中医证型的关系研究[J].湖南中医杂志,2007,23(3)：4-6.
134.孙云霞,唐蜀华.冠心病冠状动脉造影188例与中医证型及脂蛋白的相关性分析[J].中华临床医学荟莘杂志,2004,1(2)38-39.
135.邢雁伟,李尊,王阶,等.冠脉病变特征和中医证候要素关系的研究[J].辽宁中医杂志,2008,35(1)：36-38.
136.王阶,李军,姚魁武,等.冠心病心绞痛证候要素和冠脉病变的Logistic回归分析[J].辽宁中医杂志,2007,34(9)：1209-1211.
137.洪敏,李新梅,朱桂平,等.糖尿病冠心病本虚标实证与冠脉病变程度相关性研究[J].广州中医药大学学报,2007,24(1)：33-36.
138.陈伯钧,丁邦晗,张敏州.375例胸痹心痛患者临床证型的回归分析[J].江苏中医药,2005,26(6)：11-13.
139.尹克春,周文斌,陈力,等.89例冠状动脉造影与冠心病中医证型相关性研究[J].中医研究,2005,18(4)：25-26.
140.张志斌,王永炎.证候名称及分类研究的回顾与假设的提出[J].北京中医药大学学报,2003,26(2)：1-5.
1. 陶寿淇,武阳丰,主编.医疗卫生人员心血管病防治知识.北京：中国友谊出版公司,2000.
2.中华医学会心血管病分会,中华心血管病杂志编辑委员会.不稳定性心绞痛的诊断和治疗建议[J].中华心血管病杂志,2000,28(6)：409-412.
3. 邢雁伟.冠心病心绞痛证候要素诊断标准及和理化检查关系研究：[博士后出站报告].北京：中国中医科学院,2007.
4. Spertus JA, Winder JA, Dewhurst TA, et al. Development and validation of the Seattle Angina Questionnaire:a new function status measure for coronary artery disease. J Am Coil Cardiol,1995,25:333-34.
1.黄建平,张新霞,李松.心电图与冠状动脉造影诊断冠心病的评价[J].中国现代医学杂志,2005,15(10)：1529.
2.林荣,郭继鸿.心血管疾病的现代观点[M].北京：北京大学医学出版社,2005：82-99.
3.Libby P, Ridker PM.Novel inflammatory markers of coronary risk.Theory versus practice[J]. Circulation,1999,100:1148-1150.
4. Ross R.Atherosclerosis-an inflammatory disease[J].N Engl J Med,1999,340:115-126.
5. Libby P, Ridker PM, Maseri A. Inflamation and atherosclerosis[J]. Circulation,2002,105: 1135-1143.
6. Libby P.Atherosclerosis the new view[J]. Sci Am,2002,286:46-55.
7. Asano H, Sone T, Tsuboi H, et al.Diagnosis of right ventricular infarction by overlap images of simultaneous dual emission computed tomography using technetium-99 pyrophosphate and thalium-201[J].Am J Cardiol,1993,71:902908.
8. Stampfer MJ,Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians[J]JAM A,1992,268:877-881.
9.Boushey CJ,Beresford SA,Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes [J]. JAMA,1995,274:1049-1057.
10. Refsum H,Ueland PM,Nygard O, et al. Homocysteine and cardiovascular disease [J]. Ann Rev Med,1998,49:31-62.
11.Verhoef P,Kok FJ,Kruyssen DA, et al. Plasma total homocysteine,B vitamins,and risk of coronary atherosclerosis[J].Arterioscler Thromb Vasc Riol,1997,17:989-995.
12.Visaecs MCM,' Ihomas C. Hypochlorous acid disrupts the adhesive properties of subendothelial matrix[J]. Free Radic Biol Med,1997,23:401-411.
13. Hazen SL.Myeloperoxidase and plaque vulnerability,arterioscler,thromb[J]. Vasc Biol, 2004,24:1143-6.
14. Heinecke W,Daehnke HL Oxidants and antioxidants in the pathogenesis of atherosclerosis: implication for the oxidized low density lipoprotein hypothesis[J]. Atherosclerosis,1998, 14:1-15.
15. Brian J,O'Connell, Jacques Genest.High-density lipoproteins and endothelial function [J]. Circulation,2001,104-1978-83.
16.Johnson JL,Fritsche-Danielson R,Behrendt M, et al.Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability[J].Cardiovasc Res,2006, 71(3):586-595.
17. Papalambros E,Sigala F,Georgopoulos S, et al.Vascular endothelial growth factor and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with plaqued estabilization via neovascularization[J].Cerebrovasc Dis,2004, 18(2):160-165.
18. Chen F,Eriksson P,Hansson GK, et al.Expression of matrix metalloproteinase 9 and its regulators in the unstable coronaryatherosclerotic plaque[J].Int J Mol Med,2005,15 (1):57-65
19. Arno QKaski JC,Smith DA, et al.Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques[J]. Heart,2005,91(4):521-525.
20. Toyo-Oka T,Aizawa T,Suzuki N, et al. Increased plasma level of endothelinl and coronary spasm induction in patients with vasospastic angina pectoris. Circulation,1991,83:476-483.
21. Artigou JY,Salloum J,Carayon A, et al. Variations in plasma endothelin concentrations during coronary spasm. Eur Heart J,1993,14:780-784.
22. Kaski JC, Cox ID, Crook JR, et al. Differential plasma endothelin levels in subgroups of patients with angina and angiographically normal coronary arteries. Am Heart J,1998,136 (3):412-417.
23. De Lemon IA, Marrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes[J]. N Engl J Med, 2001,345:1014-1021.
24. Morrow DA, de Lemoe JA, Sebatine MS, et al.Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST elevation myocardial infarction;B-type natriuretic peptide and prognosis in TACTICS-TIMI 18[J]. J Am Coll Cardiol,2003, 41:1264-1272.
25.Campbell DJ,Munir V,Hennessy OF, et al.Plasma amino-terminal pro-brain natriuretic peptide levels in subjects presenting to the Emergeney Department with suspeeted acute coronary syndrome:possible role in seleeting patients for follow up? [J].Intern Med J, 2001,31:211-219.
26. Zimmerman GA,McIntyre TM,Prescott SM, et al. The platelet-acativating factor signaling system and its regulators in syndromes of inflammaiton and thrombosis[J]. Crit Care Med. 2002,30(5 Suppl):s294-301.
27. Louis NA,Hamilton KE,Colsan SP.Lipid mediator networks and leukocyte transmigration [J].Prostaglandins Leukot Essent Fatty Acids,2005,73(3-4):197-202.
28. NinioE. Phospholipid mediators in the vessel wall:involvement in atherosclerosis [J].Curr Opin Clin Nutr Metab Care,2005,8(2):123-131.
29. Carter AM. Inlfammation, thrombosis and acute coronary syndromes[J]. Diab VascDis Rse,2005,2(3):113-121.
30.Gum P A, Kottke-Marchant K, Poggio E D,et al.Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J].Am J Cardiol,2001,88:230-235.
31.徐成斌.血脂异常的药物治疗新进展[J].中华心血管病杂志,2001,29：189.
32.Wilsom PW. Assessing coronary heart disease risk with traditional and novel risk factors [J].Clin Cardiol,2004,27(6Suppl3):1117.
33.Lukkarinen H, Hentinen M, Assessment of quality of life with the Nottingham Health Profile among women with coronary artery disease[J]. Heart Lung,1998,27:189-199.
34.邢文华,陈晓敏,朱建华.SF-8简短量表用于冠心病病人健康相关生活质量测定的可行性[J].国外医学心血管疾病分册,2004,31(3)：181-184.
35.刘同想,孔索平,廖忠友,等.西雅图心绞痛调查量表对冠心病患者机体功能及生活质量的评估研究[J].中国行为医学科学,1997,6(2)：127-129.
36.李静,常改.西雅图量表测量冠心病患者生活质量的评价[J].中国公共卫生,2004,5(5)：594.
37.郭卉.血府逐瘀胶囊对不稳定心绞痛患者CRP、 BNP的影响[J].天津中医药,2009,26(3)：209-210.
38.张玲端,任幼红.血府逐瘀汤对气滞血瘀型CHD血浆HCY LDL-C水平的影响[J].辽 宁中医药大学学报,2009,11(6)：108-109.
39.王宝祥,董雪梅,郭爱民,等.血府逐瘀汤对不稳定型心绞痛患者血管内皮功能的影响[J].中西医结合学报,2006,4(3)：256-258.